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Abstract
N-acyl-γ-glutamyl-diaminopimelic acid is a prototype ligand for Nod1. We report a detailed SAR
of C12-γ-D-Glu-DAP. Analogues with glutaric or γ-aminobutyric acid replacing the glutamic acid
show greatly attenuated Nod1-agonistic activity. Substitution of the meso-diaminopimelic (DAP)
acid component with monoaminopimelic acid, L- or D-lysine, or cadaverine also results in
reduced activity. The free amine on DAP is crucial. However, the N-acyl group on the D-glutamyl
residue can be substituted with N-alkyl groups with full preservation of activity. The free
carboxylates on the DAP and Glu components can also be esterified, resulting in more lipophilic,
but active analogues. Transcriptomal profiling showed a dominant upregulation of IL-19, IL-20,
IL-22, and IL-24, which may explain the pronounced Th2-polarizing activity of these compounds,
and also implicate cell signaling mediated by TREM-1. These results may explain the hitherto
unknown mechanism of synergy between Nod1- and TLR-agonists, and are likely to be useful in
designing vaccine adjuvants.
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Introduction
Cellular pattern recognition receptors (PRRs) are ubiquitous innate immune sensors that
recognize specific molecular patterns present in molecules that are broadly shared by
pathogens, but are structurally distinct from host molecules1–4 PRRs include not only
membrane-bound Toll-like receptors (TLRs), members of which are expressed on the cell
surface, as well as the endocytoplasmic reticulum, but also cytosolic receptors encompassing
the Nod and RIG-I families of proteins.4;5 Nod1 and Nod2 are prototype members of the
nucleotide oligomerization domain (NOD) and ligand-recognizing leucine-rich repeat
(NLR)- containing proteins which serve to signal the presence of intracytoplasmic
peptidoglycan fragments by sensing diaminopimelic acid peptides and muramyl dipeptides,
respectively.6–9 Our interest in understanding the structural determinants of the biological
properties of ligands of PRRs stems from the potential value in harnessing innate immune
stimulatory properties in marshalling, and specifically directing subsequent adaptive
immune responses with desired immunophenotypes and profiles.10;11 We had previously
reported SAR studies on TLR2 and TLR7,12;13 and whilst studies on several other TLR
*Corresponding Author Address: Sunil A. David, Department of Medicinal Chemistry, University of Kansas, Multidisciplinary
Research Building, Room 320D, 2030 Becker Drive, Lawrence KS 66047., Tel: 785-864-1610; Fax: 785-864-1961, sdavid@ku.edu.
NIH Public Access
Author Manuscript
J Med Chem. Author manuscript; available in PMC 2012 March 10.
Published in final edited form as:













ligands continue, our attention is focused also on the intracytoplasmic NOD family of
receptors, especially Nod1. Whereas the muramyldipeptide chemotype has been extensively
studied since the early 1970s14–19 (preceding by several decades the discovery of Nod2 as
its primary receptor9;20), structure-activity relationships and signaling pathways involving
Nod1-agonistic γ-glutamyl-meso-diaminopimelic acid peptides21;22 have remained sparse.
Investigators at the Fujisawa Pharmaceutical Company reported in the early 1980s that D-
lactoyl-L-alanyl- γ-D-glutamyl-(L)-meso-diaminopimelyl-(L)-glycine and heptanoyl-γ-D-
glutamyl-(L)-meso-diaminopimelyl- D-alanine enhanced host defense in murine models of
fatal E. coli sepsis.23–27 Subsequent to the discovery that the γ-glutamyl-meso-
diaminopimelic acid (iE-DAP) fragment is the crucial pharmacophore mediating recognition
of peptidoglycan fragments by Nod1,21;22 synthetic, lipophilic, N-acyl glutamyl derivatives
have been shown to be potent Nod1 agonists.28;29 N-dodecanoyl-γ-D-glutamyl-
diaminopimelic acid (C12-iE-DAP) is now available commercially as a reference Nod1
agonist. Also noteworthy is work by Boons and colleagues who have synthesized and
evaluated DAP-containing muramyl peptides.30;31
We were keen to explore the structural space around iE-DAP scaffold for the reason that
Nod1 agonists are associated with the mobilization of adaptive immune responses with a
dominant Th2 bias, which is undesirable when a strong CD8+ cytotoxic T lymphocytic
response is required.32 We hypothesized that covalent coupling to iE-DAP of the TLR7/8-
agonistic imidazoquinolines12;33 that we have found to be extraordinarily Th1-
polarizing10;11 could lead to vaccine adjuvants with balanced Th1/Th2 immunostimulatory
phenotypes. In order to accomplish this goal, it was necessary to first determine optimal
positions on the iE-DAP backbone that would permit the generation of dual-active ‘hybrid’
molecules, combining the TLR7-agonistic imidazoquinoline and NOD1-active iE-DAP
chemotypes in a single covalently coupled construct. We report in this paper an SAR study
of Nod1-agonistic iE-DAP derivatives. Secondary screens including transcriptomal profiling
in ex vivo models using whole human blood have revealed a possible basis for the
pronounced Th2 bias of this chemotype.
Results and Discussion
The construction of orthogonally protected γ-D-glutamyl-diaminopimelic acid synthons
(Scheme 1) allowed convenient access to a number of analogues wherein the carboxyl and
amino substituents on both amino acids could be varied (Schemes 2–4). For the sake of
consistency, we designate the α-amino group on the D-Glu as N, and the γ-amino group on
the diaminopimelic acid (DAP) residue as N′. We used the commercially available
diaminopimelic acid (6; mixture of 4 isomers), since derivatives of all four isomers have
been shown to be active.28;29 Esters of DAP proved surprisingly difficult to obtain by a
number of conventional methods, necessitating sequential N-Boc protection of the amines,
esterification (as benzyl or ethyl) of the carboxylic acids, deprotection of the N-Boc groups,
followed by mono-N-Boc protection using stoichiometric equivalents of Boc2O. N-Fmoc-D-
Glu-α-benzyl/allyl esters (4, 5 respectively) were coupled to the mono-N-Boc-
diaminopimelic acid diesters (9 or 10) using standard protocols to afford the orthogonally
protected synthons (11–13; Scheme 1). N-Fmoc (D-Glu) deprotection, followed by acylation
with lauroyl chloride and subsequent deprotection of the N-Boc and O-Bn groups yielded
C12-iE-DAP (16; Scheme 2), the activity of which was identical to commercially available
reference compound with EC50 values of ~30 pM (Fig. 1A).
The N′-acyl (DAP) compound (18), the N,N′-diacyl (D-Glu, and DAP, respectively)
analogue (20), as well as N-alkyl (22) and N,N-dialkyl analogues (26–28) were also
synthesized from synthon 11 (Scheme 2). Our initial attempts at converting the N′ amine to a
guanidine group resulted in an undesired cyclization-elimination reaction to form the
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aminoimidazolone 30; this was obviated by the use of N,N′-di- Boc-1H-pyrazole-1-
carboxamidine as the guanidination reagent, affording the desired product 32 (Scheme 2).
Next, analogues were synthesized from 12 with the acyl group on the α-amine of D-Glu
transposed to the α-carboxylic acid group as either the undecanoyl ester (35), the 1-
aminoundecane-derived amide (37), as well as the N-acyl long-chain ester 41 (Scheme 3).
The N-guanidino ester analogue 43, as well as the α-D-Glu ethyl ester derivative of C12-iE-
DAP (45) were also obtained from 12 (Scheme 3). The α-D-Glu thioester DAP ethyl ester
analogue (48) and DAP ethyl ester derivative of C12-iE-DAP (50) were synthesized from
synthon 13 (Scheme 4).
In order to examine the importance of the α-amino and carboxyl groups of D-Glu, γ-
aminobutyric acid (des-carboxyl, 53) or glutaric acid (des-amino, 56) were coupled to the
DAP derivative 9 as depicted in Scheme 5. Similarly, suitably protected mono-aminopimelic
acid 58, D- and L-lysine derivatives (62–65; Scheme 6), and commercially available N-Boc-
cadaverine and D, L-α-amino-ε-caprolactam were used to examine the roles of the amine
and carboxyl groups of DAP (Scheme 7).
The N-acyl on the D-Glu residue appears to be optimal for Nod1-agonistic activity since the
transposition of the acyl group to the N′ position on DAP (18), or diacylation at N and N′
(20) resulted in substantial decrease in activity (Table 1). The substitution of the N-acyl
(C12) group with N-alkyl (22) led to virtually identical activity (27 pM versus 23 pM, Table
1). Compounds with C8 or C16 N,N-dialkyl groups (26, 28) displayed attenuated potency
while the C12 N,N-dialkyl compound 27 displayed a rather dramatic increase in potency,
with residual partial activity evident even at very high dilutions (Table 1, 27Fig. 1).
Compound was the most potent analogue identified in this study. The primary amines on
both the DAP and D-Glu segments were found to be crucial; the guanidino analogues 32 and
43, as well as the aminoimidazolone analogue 30 exhibited diminished activity.
We next examined the importance of the free α-carboxyl group on D-Glu. The potencies of
the undecanoyl ester of iE-DAP (35), as well as the ethyl ester of C12-iE-DAP (45) were
comparable to that of the reference compound, C12-iE-DAP (16). The undecanoyl ester of
C12-iE-DAP (41), and the thioester analogue 48 also retained modest activity. The 1-
aminoundecane-derived amide analogue (37), however, was substantially less active.
Augmented activity in 35 and 45 appears to be related to neither net charge nor bulk
hydrophobicity, both of which could be reasonably expected to modulate transmembrane
permeation, and consequent presentation of the ligand to the intracellular Nod1 receptor.
The net charge at physiological pH of 35 and 37 is zero, whilst that of 41 and 45 is −1. We
surmised that the higher potency of 45 relative to 41 could be due to the more facile
hydrolytic cleavage by intracellular esterases of the shorter, ethyl ester of 45, but our
observation that the rate and kinetics of NF-κB induction for both compounds were very
similar (data not shown) is not in agreement with our conjecture, and we do not yet
understand the basis for the difference in potencies of these analogues. Substitution of the N-
acyl D-Glu fragment with either N-acyl γ-aminobutyric acid (53, des-α-carboxyl analogue),
or the undecanoyl ester of glutaric acid (56, des-α-amino analogue) resulted only in
considerable loss in Nod1-agonistic activity. Taken together, the above SAR data suggest
that considerable ‘plasticity’ exists in the recognition of the D-Glu fragment. Indeed, a plot
of the potencies of these analogues displays an unexpectedly diffuse, near-uniform
distribution of EC50 values (Fig. 1B), unlike the well-demarcated and discrete SAR that we
had previously observed for TLR2-13 and TLR7-active12 compounds.
In contradistinction to the broad and diffuse SAR for D-Glu fragment, the DAP portion of
the molecule is far more stringent in determining Nod1 agonism. Whereas esterification of
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carboxyl groups of DAP (50) is tolerated, substitution with mono-aminopimelic acid (67,
des-amino) or cadaverine (69, des-dicarboxyl) resulted in abrogation of activity. The meso-
diaminopimelic acid-containing peptidoglycan is specific for Gram-negative bacteria, and
the corresponding homologue in Gram-positive organisms is L-lysine coupled via its α-
amine to γ-D-glutamyl residue (77), the activity of which is ~10-fold less than that of
16.34;35 The D-lysine analogue 73 is bereft of any activity. The unnatural ε-amine-coupled
lysine analogues were also evaluated. The D-lysine analogue 75 was found to be four-fold
more active than 79, its L-lysine congener.
Primary assay readouts using cell-culture systems may not always accurately reflect in vivo
behavior owing to a variety of reasons, including differential plasma protein binding (that
we ourselves have observed and characterized),36 and we therefore wished to confirm that
the 27 was indeed more potent than 16, the reference Nod1 agonist, in ex vivo assays
employing whole human blood. Although Nod1 agonists have previously been shown to
enhance neutrophil recruitment in mice,34 a recent report employing synthetic, non-acylated,
γ-glutamyl-meso-diaminopimelic acid dipeptide indicated that Nod1-specific responses
could not be elicited in isolated human neutrophils.37 Using an ex vivo system using fresh,
whole human blood that we have established for immunoprofiling innate immune stimuli,
10;13;38 both p38 MAPK39 and CD11b40 were upregulated in a dose-dependent manner,
with 27 being more potent than 16 (Fig. 2). Indeed, the non-acylated, γ-glutamyl-meso-
diaminopimelic acid dipeptide was inactive in our primary and secondary screens (data not
shown), emphasizing the requirement of an N-acyl functionality on glutamic acid.
Recent findings using murine models of immunization indicate that Nod1 engagement
drives B and T cell immunity with a predominant Th2 polarization, and additional Th17
priming.32 However, mechanisms underlying the induction of strong Th2-biased immune
responses have remained obscure. Given the significant differences between species-
dependent recognition of innate immune ligands,11 we desired to evaluate whether surrogate
markers of Th2-skewed responses could be observed in human ex vivo model systems, in the
hope that these studies may also help uncover signaling events determining Th2
polarization. Transcriptomal profiling experiments using human blood revealed a very
prominent upregulation of Class II helical cytokines by 27, especially members of the IL-10
superfamily41 including IL-19, IL-20, IL-22, and IL-24 (Table 2); these cytokines,
especially IL-19,42–45 have been shown to drive Th2-polarized responses. We have never
before observed this particular constellation of cytokines in our earlier10 (and ongoing)
immunoprofiling studies, and we are excited in no small measure that quantifying the
induction of IL-19 and related cytokines may have predictive value as biomarkers and
surrogate signatures for Th2 induction in immunoprofiling vaccine adjuvants, and may
perhaps supplant the necessity of long and laborious immunization experiments which
typically involve large numbers of animals. Also observed, as could be expected in the
context of Th17-induction,32 was the upregulation of IL-17. Similar responses were
observed with 16, but of lower magnitude, consistent with the lower potency of 16 (data not
shown).
Further analyses of gene transcripts induced by 27 yielded the unexpected finding that
exposure of human blood to 27 results in the activation of pathways involving signaling
mediated by Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1; Fig. 3). TREM-1
is a recently-discovered receptor expressed on the cell surface of monocytes and neutrophils,
and plays an important role in amplifying myeloid cell-activated inflammatory responses.46–
48 Our observation of the upregulation of TREM-1 signaling components may explain the
hitherto unknown mechanism of synergy between Nod1- and TLRagonists. 32;34;49;50
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The overarching objective that led to our work on Nod1 ligands was not so much to
synthesize higher potency compounds, but rather to understand SAR that would permit us to
covalently couple other innate immune ligands12;13;33 to the iE-DAP scaffold in order to test
the hypothesis that such hybrids may imbue a Th1-Th2 balanced, yet effective vaccine
adjuvants. The studies reported here indicate that various substitutions and modifications on
the γ-D-glutamyl moiety are tolerated whereas the diaminopimelic acid fragment is far more
stringent. The α-carboxylic acid of D-Glu appears to be optimal for coupling with other
innate immune ligands, and work in this area is in progress. Secondary and tertiary screens,
including transcriptomal profiling have shed light on the possible mechanisms underlying
the strong Th2 bias of Nod1 ligands, and of synergy with other innate immune stimuli.
Experimental Section
Chemistry
All of the solvents and reagents used were obtained commercially and used as such unless
noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under
reduced pressure using standard rotary evaporators. Flash column chromatography was
carried out using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf
(Teledyne-Isco, Lincoln, NE) instrument unless otherwise mentioned, while thin-layer
chromatography was carried out on silica gel CCM pre-coated aluminum sheets. Purity for
all final compounds was confirmed to be at least 97% by LC-MS using a Zorbax Eclipse
Plus 4.6 mm x 150 mm, 5 μm analytical reverse phase C18 column with H2O-isopropanol or
H2O-CH3CN gradients (with 0.1% CF3COOH in both mobile phases) and an Agilent ESI-
TOF mass spectrometer (mass accuracy of 5 ppm) operating in the positive ion (or negative
ion, as appropriate) acquisition mode.
Synthesis of Compound 2: (R)-1-Benzyl 5-tert-butyl 2-((tert-butoxycarbonyl)amino)
pentanedioate
To a solution of 1 (1 g, 3.29 mmol) in anhydrous DMF, were added HBTU (1.38 g, 3.62
mmol), triethylamine (0.5 mL, 3.62 mmol), benzyl alcohol (682 μL, 6.59 mmol) and a
catalytic amount of DMAP. The reaction mixture was stirred for 4 hours, followed by
evaporation of the solvent under reduced pressure. The residue was then dissolved in ethyl
acetate and washed with water. The organic solvent was dried over anhydrous sodium
sulfate, filtered, evaporated under reduced pressure to obtain the crude product which was
purified using column chromatography (10% EtOAc/hexanes) to obtain the compound 2
(1.14 g, 88 %). 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.31 (m, 5H), 5.16 (dt, J = 23.2, 11.5
Hz, 3H), 4.35 (dd, J = 13.0, 8.2 Hz, 1H), 2.35 – 2.22 (m, 2H), 2.13 (td, J = 13.3, 7.0 Hz,
1H), 1.92 (tt, J = 14.7, 7.5 Hz, 1H), 1.43 (s, 18H). 13C NMR (126 MHz, CDCl3) δ 172.09,
172.06, 155.39, 131.57, 118.82, 80.74, 79.93, 65.95, 53.11, 31.60, 28.30, 28.06, 27.89,
27.68. MS (ESI) calculated for C21H31NO6, m/z 393.22, found 416.22 (M + Na)+.
Synthesis of Compound 3: (R)-1-Allyl 5-tert-butyl 2-((tert-butoxycarbonyl)amino)
pentanedioate
To a solution of 1 (1 g, 3.29 mmol) in anhydrous DMF, were added HBTU (1.38 g, 3.62
mmol), triethylamine (0.5 mL, 3.62 mmol), allyl alcohol (450 μL, 6.59 mmol) and a
catalytic amount of DMAP. The reaction mixture was stirred for 4 hours, followed by
evaporation of the solvent under reduced pressure. The residue was then dissolved in ethyl
acetate and washed with water. The organic solvent was dried over anhydrous sodium
sulfate, filtered, evaporated under reduced pressure to obtain the crude product which was
purified using column chromatography (10% EtOAc/hexanes) to obtain the compound 3
(1.0 g, 90 %). 1H NMR (500 MHz, CDCl3) δ 5.91 (ddt, J = 16.3, 10.6, 5.8 Hz, 1H), 5.34
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(dd, J = 17.2, 1.3 Hz, 1H), 5.26 (dd, J = 10.4, 0.7 Hz, 1H), 5.11 (d, J = 8.0 Hz, 1H), 4.64 -
4.63 (m, 2H), 4.33 (dd, J = 13.2, 8.3 Hz, 1H), 2.38 - 2.26 (m, 2H), 2.17-2.11 (m, 1H),
1.96-1.88 (m, 1H), 1.45 (s, 9H), 1.44 (s, 9 H). 13C NMR (126 MHz, CDCl3) δ 172.05,
172.02, 155.35, 131.53, 118.78, 80.70, 79.89, 65.91, 53.07, 31.56, 28.26, 28.02, 27.85,
27.64. MS (ESI) calculated for C17H29NO6, m/z 343.20, found 366.19 (M + Na)+.
Synthesis of Compound 4: (R)-4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-
(benzyloxy)- 5-oxopentanoic acid
The solution of 2 (1 g, 2.54 mmol) in trifluoroacetic acid was stirred for 1 hour, followed by
removal of the solvent by purging nitrogen and drying under vacuum to obtain the
trifluoroacetate salt. To the solution of trifluoroacetate salt in dioxane, the aqueous solution
of sodium carbonate (810 mg, 7.64 mmol) was added at 10 °C. The reaction mixture was
stirred at room temperature for 10 min, followed by the addition of FmocCl (722 mg, 2.79
mmol) solution in dioxane. The reaction mixture was stirred at room temperature for 16 hrs,
followed by removal of the solvent under reduced pressure. The residue was dissolved in
ethyl acetate and water, and the solution was acidified using 10% HCl until pH was ~1. The
aqueous layer was washed with ethyl acetate. The ethyl acetate was dried over anhydrous
sodium sulfate, filtered, evaporated under reduced pressure to obtain the crude product
which was purified using column chromatography (40% EtOAc/hexanes) to obtain the
compound 4 (1.0 g, 91 %). 1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 7.5 Hz, 2H), 7.56 (d,
J = 7.4 Hz, 2H), 7.33 (qd, J = 15.0, 7.2 Hz, 9H), 5.47 (d, J = 8.2 Hz, 1H), 5.19 – 5.06 (m,
2H), 4.53 – 4.30 (m, 3H), 4.16 (dd, J = 15.6, 8.8 Hz, 1H), 2.48 – 2.12 (m, 3H), 1.94 (dt, J =
14.5, 7.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 177.59, 171.91, 156.27, 143.99, 143.84,
141.50, 141.49, 135.19, 128.88, 128.81, 128.56, 127.95, 127.30, 125.29, 125.26, 120.21,
120.20, 67.73, 67.34, 53.42, 47.32, 29.91, 27.64. MS (ESI) calculated for C27H25NO6, m/z
459.16, found 482.17 (M + Na)+.
Synthesis of Compound 5: (R)-4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-
(allyloxy)-5- oxopentanoic acid
The solution of compound 3 (1 g, 2.91 mmol) in trifluoroacetic acid was stirred for 1 hour,
followed by removal of the solvent by purging nitrogen and drying under vacuum to obtain
the trifluoroacetate salt. To the solution of trifluoroacetate salt in dioxane, the aqueous
solution of sodium carbonate (926 mg, 8.74 mmol) was added at 10 °C. The reaction
mixture was stirred at room temperature for 10 min, followed by the addition of FmocCl
(830 mg, 3.2 mmol) solution in dioxane. The reaction mixture was stirred at room
temperature for 16 hours, followed by removal of the solvent under reduced pressure. The
residue was dissolved in ethyl acetate and water, and the solution was acidified using 10%
HCl until pH was ~1. The aqueous layer was washed with ethyl acetate. The ethyl acetate
layer was dried over anhydrous sodium sulfate, filtered, evaporated under reduced pressure
to obtain the crude product which was purified using column chromatography (40% EtOAc/
hexanes) to obtain the compound 5 (1.1 g, 92 %). 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J =
7.5 Hz, 2H), 7.59 (d, J = 7.1 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 5.90
(ddd, J = 22.5, 11.0, 5.7 Hz, 1H), 5.44 (d, J = 8.1 Hz, 1H), 5.30 (dd, J = 27.7, 13.7 Hz, 2H),
4.65 (d, J = 5.5 Hz, 2H), 4.58 – 4.35 (m, 3H), 4.21 (t, J = 6.8 Hz, 1H), 2.58 – 2.17 (m, 3H),
2.07 – 1.92 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 172.70, 172.54, 155.72, 155.57,
135.49, 128.74, 128.57, 128.43, 80.07, 67.19, 67.14, 53.27, 32.24, 28.47, 28.45, 21.48,
21.19, 21.08. MS (ESI) calculated for C23H23NO6, m/z 409.15, found 432.14 (M + Na)+.
Synthesis of Compound 7: Dibenzyl 2,6-bis((tert-butoxycarbonyl)amino)heptanedioate
To a solution of compound 6 (1 g, 5.25 mmol) in water, were added di-tert-butyl
dicarbonate (4.58 g, 21.0 mmol) and triethylamine (2.92 mL, 21.0 mmol). The reaction
mixture was stirred for 6 hours, followed by removal of the solvent under reduced pressure
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to obtain the residue. To the solution of residue in anhydrous DMF, were added HBTU (4.38
g, 11.55 mmol), triethylamine (1.6 mL, 11.55 mmol), benzyl alcohol (1.63 mL, 15.75 mmol)
and a catalytic amount of DMAP. The reaction mixture was stirred for 8 hours, followed by
evaporation of the solvent under reduced pressure. The residue was then dissolved in ethyl
acetate and washed with water. The organic solvent was dried over anhydrous sodium
sulfate, filtered, evaporated under reduced pressure to obtain the crude product which was
purified using column chromatography (8% EtOAc/hexanes) to obtain the compound 7
(2.48 g, 83%). 1H NMR (500 MHz, CDCl3) δ 7.44 – 7.29 (m, 10H), 5.13 (dt, J = 12.4, 8.3
Hz, 6H), 4.29 (s, 2H), 1.85 – 1.71 (m, 2H), 1.68 (s, 2H), 1.49 – 1.31 (m, 20H). 13C NMR
(126 MHz, CDCl3) δ 172.70, 172.54, 155.72, 155.57, 135.49, 128.74, 128.57, 128.43, 80.07,
67.19, 67.14, 53.27, 32.24, 28.47, 28.45, 21.48, 21.19, 21.08. MS (ESI) calculated for
C31H42N2O8, m/z 570.29, found 593.27 (M + Na)+.
Synthesis of Compound 8: Diethyl 2,6-bis((tert-butoxycarbonyl)amino)heptanedioate
To a solution of compound 6 (1 g, 5.25 mmol) in water, were added di-tert-butyl
dicarbonate (4.58 g, 21.0 mmol) and triethylamine (2.92 mL, 21.0 mmol). The reaction
mixture was stirred for 6 hours, followed by removal of the solvent under reduced pressure
to obtain the residue. To the solution of residue in anhydrous DMF, were added HBTU (4.38
g, 11.55 mmol), triethylamine (1.6 mL, 11.55 mmol), ethyl alcohol (0.92 mL, 15.75 mmol)
and a catalytic amount of DMAP. The reaction mixture was stirred for 6 hours, followed by
evaporation of the solvent under reduced pressure. The residue was then dissolved in ethyl
acetate and washed with water. The organic solvent was dried over anhydrous sodium
sulfate, filtered, evaporated under reduced pressure to obtain the crude product which was
purified using column chromatography (8% EtOAc/hexanes) to obtain the compound 8 (2.0
g, 85%). 1H NMR (500 MHz, CDCl3) δ 5.17 – 4.99 (m, 2H), 4.30 – 4.08 (m, 6H), 1.84 –
1.74 (m, 2H), 1.72 – 1.55 (m, 4H), 1.48 – 1.31 (m, 18H), 1.25 (t, J = 7.1 Hz, 6H). 13C NMR
(126 MHz, CDCl3) δ 173.24, 173.06, 156.07, 155.92, 80.33, 68.61, 61.80, 53.58, 39.17,
32.74, 32.67, 30.80, 29.38, 28.81, 28.79, 28.71, 24.19, 23.45, 21.82, 21.47, 14.64, 14.52. MS
(ESI) calculated for C21H38N2O8, m/z 446.26, found 469.26 (M + Na)+.
Synthesis of Compound 9: Dibenzyl 2-amino-6-((tert-butoxycarbonyl)amino)heptanedioate
The compound 7 (2 g, 3.5 mmol) was dissolved in 10 mL of HCl-dioxane and stirred for 2
hours. The solvent was then removed under vacuum to obtain the hydrochloride salt, which
was then dissolved in methanol. The triethylamine was added to solution until pH ~ 7,
followed by gradual addition of di-tert-butyl dicarbonate (764 mg, 3.5 mmol). The reaction
mixture was stirred for 30 minutes, followed by evaporation of the solvent under reduced
pressure to obtain the crude product, which was then purified using column chromatography
(5% MeOH/CH2Cl2) to obtain the compound 9 (640 mg, 39%). 1H NMR (500 MHz,
CDCl3) δ 7.45 – 7.28 (m, 10H), 5.23 – 5.09 (m, 4H), 5.03 (t, J = 7.3 Hz, 1H), 4.41 – 4.23
(m, 1H), 3.41 (td, J = 8.1, 5.2 Hz, 1H), 1.85 – 1.50 (m, 6H), 1.49 – 1.34 (m, 11H). 13C NMR
(126 MHz, CDCl3) δ 176.17, 176.14, 173.01, 155.83, 136.10, 135.84, 129.25, 129.09,
129.06, 128.88, 128.78, 80.36, 67.46, 67.16, 67.14, 54.70, 54.68, 53.80, 53.74, 34.73, 34.66,
32.77, 32.74, 28.77, 21.93. MS (ESI) calculated for C26H34N2O6, m/z 470.24, found 471.24
(M + H)+.
Synthesis of Compound 10: Diethyl 2-amino-6-((tert-butoxycarbonyl)amino)heptanedioate
The compound 8 (1 g, 2.24 mmol) was dissolved in 5 mL of HCl-dioxane and stirred for 2.5
hours. The solvent was then removed under vacuum to obtain the hydrochloride salt, which
was then dissolved in methanol. The triethylamine was added to solution until pH ~ 7,
followed by gradual addition of di-tert-butyl dicarbonate (490 mg, 2.24 mmol). The reaction
mixture was stirred for 30 minutes, followed by evaporation of the solvent under reduced
pressure to obtain the crude product, which was then purified using column chromatography
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(5% MeOH/CH2Cl2) to obtain the compound 10 (271 mg, 35%). 1H NMR (500 MHz,
CDCl3) δ 5.31 (dd, J = 31.4, 7.9 Hz, 1H), 4.28 – 4.16 (m, 5H), 3.96 (bs, 1H), 2.04 – 1.88 (m,
2H), 1.88 – 1.76 (m, 1H), 1.73 – 1.62 (m, 1H), 1.62 – 1.43 (m, 2H), 1.42 (s, 9H), 1.32 – 1.24
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 176.13, 176.08, 172.94, 155.59, 80.00, 61.50,
61.08, 54.40, 53.50, 53.44, 34.56, 34.53, 32.65, 32.62, 28.50, 21.73, 21.67, 14.42, 14.37. MS
(ESI) calculated for C16H30N2O6, m/z 346.21, found 347.21 (M + H)+.
Synthesis of Compound 11: (5R)-Tribenzyl 1-(9H-fluoren-9-yl)-18,18-dimethyl-3,8,16-trioxo-
2,17-dioxa-4,9,15-triazanonadecane-5,10,14-tricarboxylate
To a solution of 4 (500 mg, 1.08 mmol) in anhydrous dichloromethane, were added 9 (522
mg, 1.11 mmol), polystyrene bound carbodiimide (967 mg, 1.19 mmol) and a catalytic
amount of polystyrene bound DMAP. The reaction mixture was stirred at room temperature
for 4 hours, followed by filtration to remove the solid resin. The filtrate was evaporated
under vacuum to obtain the residue which was then purified using column chromatography
(35% EtOAc/hexanes) to obtain the compound 11 (748 mg, 76%). 1H NMR (500 MHz,
CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.3 Hz, 2H), 7.39 – 7.30 (m, 19H), 6.59 –
6.49 (m, 0.50H), 6.28 (s, 0.50H), 5.71 (dd, J = 25.1, 7.7 Hz, 1H), 5.24 – 5.04 (m, 7H), 4.56
(d, J = 6.6 Hz, 1H), 4.50 – 4.33 (m, 3H), 4.33 – 4.15 (m, 2H), 2.31 – 2.16 (m, 2H), 2.03 –
1.90 (m, 2H), 1.85 – 1.75 (m, 2H), 1.70 – 1.51 (m, 2H), 1.40 – 1.37 (m, 11H). 13C NMR
(126 MHz, CDCl3) δ 172.65, 172.57, 172.16, 172.09, 171.97, 171.82, 156.53, 155.78,
144.10, 143.85, 141.51, 141.48, 135.55, 135.36, 128.85, 128.83, 128.81, 128.73, 128.64,
128.60, 128.53, 128.45, 127.92, 127.30, 125.36, 120.18, 80.12, 67.59, 67.41, 67.33, 67.24,
53.63, 53.53, 53.33, 52.21, 47.37, 47.34, 32.32, 32.22, 31.73, 28.93, 28.51, 21.54, 21.43,
21.28, 21.13. MS (ESI) calculated for C53H57N3O11, m/z 911.40, found 934.39 (M + Na)+.
Synthesis of Compound 12: (5R)-5-Allyl 10,14-dibenzyl 1-(9H-fluoren-9-yl)-18,18-dimethyl-
3,8,16-trioxo-2,17-dioxa-4,9,15-triazanonadecane-5,10,14-tricarboxylate
To a solution of 5 (500 mg, 1.22 mmol) in anhydrous dichloromethane, were added 9 (585
mg, 1.24 mmol), polystyrene bound carbodiimide (1.09 g, 1.34 mmol) and a catalytic
amount of polystyrene bound DMAP. The reaction mixture was stirred at room temperature
for 4 hours, followed by filtration to remove the solid resin. The filtrate was evaporated
under reduced pressure to obtain the residue which was then purified using column
chromatography (35% EtOAc/hexanes) to obtain the compound 12 (830 mg, 79%). 1H
NMR (400 MHz, CDCl3) δ 7.79 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 6.6 Hz, 2H), 7.46 – 7.30
(m, 14H), 6.69 – 6.30 (m, 1H), 5.91 (dd, J = 19.3, 12.8 Hz, 1H), 5.72 (dd, J = 20.3, 7.6 Hz,
1H), 5.35 (d, J = 17.2 Hz, 1H), 5.27 (d, J = 10.4 Hz, 1H), 5.22 – 5.04 (m, 5H), 4.70 – 4.56
(m, 3H), 4.52 – 4.36 (m, 3H), 4.35 – 4.19 (m, 2H), 2.38 – 2.20 (m, 3H), 1.98 (dd, J = 19.2,
8.3 Hz, 1H), 1.91 – 1.56 (m, 4H), 1.44 (s, 11H). 13C NMR (126 MHz, CDCl3) δ 172.66,
172.56, 172.20, 172.12, 171.99, 171.85, 156.56, 155.83, 144.09, 143.86, 141.51, 135.54,
135.45, 131.59, 128.83, 128.71, 128.64, 128.51, 127.94, 127.31, 125.35, 120.19, 119.40,
119.36, 119.32, 80.13, 67.43, 67.33, 67.23, 66.42, 53.61, 53.53, 53.33, 52.24, 47.37, 32.41,
32.34, 31.84, 31.75, 31.61, 29.00, 28.51, 21.46, 21.27, 21.14. MS (ESI) calculated for
C49H55N3O11, m/z 861.38, found 884.33 (M + Na)+.
Synthesis of Compound 13: (5R)-5-Benzyl 10,14-diethyl 1-(9H-fluoren-9-yl)-18,18-dimethyl-
3,8,16-trioxo-2,17-dioxa-4,9,15-triazanonadecane-5,10,14-tricarboxylate
To a solution of 4 (195 mg, 0.425 mmol) in anhydrous dichloromethane, were added 10
(150 mg, 0.43 mmol), polystyrene bound carbodiimide (367 mg, 0.467 mmol) and a
catalytic amount of polystyrene bound DMAP. The reaction mixture was stirred at room
temperature for 4 hours, followed by filtration to remove the solid resin. The filtrate was
evaporated under reduced pressure to obtain the residue which was then purified using
column chromatography (30% EtOAc/hexanes) to obtain the compound 13 (232 mg,
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70%). 1H NMR (500 MHz, CDCl3) δ 7.79 – 7.69 (m, 2H), 7.59 (dd, J = 21.4, 11.5 Hz, 2H),
7.55 – 7.26 (m, 9H), 6.55 (dd, J = 27.8, 7.3 Hz, 1H), 6.31 (dd, J = 18.6, 7.1 Hz, 1H), 5.75
(dd, J = 27.6, 7.7 Hz, 1H), 5.27 – 5.05 (m, 3H), 4.61 – 4.33 (m, 4H), 4.28 – 4.04 (m, 6H),
2.31 – 2.20 (m, 2H), 2.04 – 1.93 (m, 1H), 1.89 – 1.52 (m, 5H), 1.46 – 1.36 (m, 9H), 1.34 –
1.21 (m, 7H). 13C NMR (126 MHz, CDCl3) δ 156.50, 144.11, 143.88, 141.52, 135.38,
131.11, 129.02, 128.87, 128.76, 128.66, 128.59, 127.93, 127.31, 125.37, 120.19, 80.07,
68.37, 67.61, 67.29, 61.75, 61.57, 53.29, 52.13, 47.36, 38.92, 32.48, 32.37, 31.74, 30.56,
29.13, 28.53, 23.94, 23.20, 21.44, 14.37, 14.28, 11.12. MS (ESI) calculated for
C43H53N3O11, m/z 787.37, found 810.37 (M + Na)+.
Synthesis of Compound 14: Dibenzyl 2-((R)-4-amino-5-(benzyloxy)-5-oxopentanamido)-6-
((tert-butoxycarbonyl)amino)heptanedioate
The compound 11 (500 mg, 0.55 mmol) was dissolved in 10 mL of dichloromethane,
followed by the addition of 3 mL of piperidine. The reaction mixture was stirred for 15
minutes, followed by removal of the solvent under reduced pressure. The crude was purified
using column chromatography (5% MeOH/CH2Cl2) to obtain the compound 14 (347 mg,
92%). 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.31 (m, 15H), 6.57 (dt, J = 36.1, 8.8 Hz, 1H),
5.25 – 5.05 (m, 7H), 4.59 (d, J = 5.6 Hz, 1H), 4.28 (s, 1H), 3.52 (dd, J = 8.2, 5.1 Hz, 1H),
2.36 (qt, J = 21.1, 6.8 Hz, 2H), 2.13 (dd, J = 12.5, 6.0 Hz, 1H), 1.93 – 1.50 (m, 7H), 1.49 –
1.32 (m, 11H). 13C NMR (101 MHz, CDCl3) δ 176.03, 172.79, 172.67, 136.10, 135.85,
129.15, 129.12, 129.01, 128.94, 128.85, 128.76, 67.53, 67.32, 54.38, 54.01, 53.70, 52.40,
33.12, 33.00, 32.17, 30.48, 30.31, 28.82, 21.78, 21.59. MS (ESI) calculated for
C38H47N3O9, m/z 689.33, found 690.33 (M + H)+.
Synthesis of Compound 15: (15R)-Tribenzyl 2,2-dimethyl-4,12,17-trioxo-3-oxa-5,11,16-
triazaoctacosane-6,10,15-tricarboxylate
To a solution of 14 (200 mg, 0.29 mmol) in pyridine, were added lauroyl chloride (82.6 μL,
0.34 mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 6 hours,
followed by evaporation of the solvent under reduced pressure to obtain the residue, which
was then dissolved in dichloromethane and washed with water. The organic solvent was
dried over anhydrous sodium sulfate, filtered, evaporated under reduced pressure to obtain
the crude product which was purified using column chromatography (50% EtOAc/hexanes)
to obtain the compound 15 (209 mg, 83%). 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.27 (m,
15H), 6.98 (dd, J = 16.0, 7.8 Hz, 0.50H), 6.57 – 6.46 (m, 1.50H), 5.22 – 5.07 (m, 7H), 4.76 –
4.70 (m, 0.50H), 4.61 – 4.51 (m, 1.50H), 4.31 – 4.20 (m, 1H), 2.28 – 2.16 (m, 5H), 1.98 –
1.57 (m, 11H), 1.50 – 1.36 (m, 6H), 1.32 – 1.20 (m, 17H), 0.88 (t, J = 7.0 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 172.68, 172.61, 172.46, 172.38, 172.33, 172.24, 172.20, 172.12,
172.04, 135.57, 135.45, 135.40, 128.85, 128.84, 128.82, 128.71, 128.65, 128.62, 128.58,
128.53, 128.48, 128.47, 80.10, 67.53, 67.23, 53.39, 52.29, 51.86, 36.83, 36.77, 32.53, 32.40,
32.12, 31.58, 29.84, 29.82, 29.70, 29.56, 29.51, 29.18, 28.54, 25.86, 25.79, 22.90, 14.34. MS
(ESI) calculated for C50H69N3O10, m/z 871.50, found 894.50 (M + Na)+.
Synthesis of Compound 16: 2-Amino-6-((R)-4-carboxy-4-dodecanamidobutanamido)
heptanedioic acid
G3The compound 15 (50 mg, 57.3 μmol) was dissolved in methanol, followed by the
addition of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi
hydrogen pressure for 2 hours, followed by filtration through celite bed. The solvent was
removed under reduced pressure to obtain the residue, which was dissolved in 5 mL of
trifluoroacetic acid and stirred for 30 minutes, followed by removal of the solvent by
purging nitrogen and drying under vacuum to obtain the trifluoroacetate salt of the
compound 16 (35 mg, quantitative yield). 1H NMR (500 MHz, MeOD) δ 4.46 – 4.30 (m,
2H), 3.78 – 3.68 (m, 1H), 2.35 (t, J = 5.6 Hz, 2H), 2.27 – 2.10 (m, 3H), 1.88 (ddd, J = 24.9,
Agnihotri et al. Page 9













20.5, 16.8 Hz, 4H), 1.75 – 1.66 (m, 1H), 1.65 – 1.47 (m, 4H), 1.36 – 1.21 (m, 16H), 0.87 (t,
J = 6.8 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 176.64, 175.50, 175.02, 173.29, 55.13,
54.97, 53.42, 53.16, 37.09, 36.99, 33.25, 33.04, 32.52, 32.45, 32.38, 31.64, 31.53, 31.47,
30.92, 30.82, 30.65, 30.50, 28.82, 28.58, 28.30, 27.14, 27.11, 23.89, 23.06, 22.71, 22.63,
14.59. MS (ESI) calculated for C24H43N3O8, m/z 501.31, found 502.33 (M + H)+.
Synthesis of Compound 17: (5R)-Tribenzyl 1-(9H-fluoren-9-yl)-3,8,16-trioxo-2-oxa-4,9,15-
triazaheptacosane-5,10,14-tricarboxylate
The compound 11 (100 mg, 0.10 mmol) was dissolved in 5 mL of trifluoroacetic acid and
stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and drying
under vacuum to obtain the trifluoroacetate salt. To the solution of trifluoroacetate salt in
anhydrous dichloromethane, were added lauroyl chloride (39 μL, 0.16 mmol), triethylamine
(30 μL, 0.22 mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 2
hours, followed by complete removal of the solvent under reduced pressure. The residue was
then dissolved in dichloromethane and washed with water. The organic solvent was dried
over sodium sulfate, filtered, evaporated under reduced pressure to obtain the crude product
which was purified using column chromatography (40% EtOAc/hexanes) to obtain the
compound 17 (103 mg, 95%). 1H NMR (400 MHz, CDCl3) δ 7.83 – 7.70 (m, 2H), 7.68 –
7.52 (m, 2H), 7.46 – 7.27 (m, 19H), 6.27 – 6.06 (m, 1H), 5.93 – 5.74 (m, 1H), 5.30 – 5.04
(m, 6H), 4.67 – 4.28 (m, 5H), 4.28 – 4.18 (m, 1H), 2.33 – 2.26 (m, 2H), 2.22 – 2.13 (m, 2H),
2.01 (dd, J = 15.1, 7.4 Hz, 1H), 1.92 – 1.79 (m, 2H), 1.79 – 1.66 (m, 3H), 1.64 – 1.56 (m,
2H), 1.48 – 1.17 (m, 19H), 0.90 (t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.48,
172.36, 172.06, 172.02, 156.61, 143.74, 141.50, 135.39, 128.84, 128.70, 128.47, 127.92,
127.30, 125.35, 120.17, 67.55, 67.41, 67.31, 53.83, 51.87, 51.64, 47.35, 36.69, 32.19, 32.11,
31.62, 29.83, 29.69, 29.54, 29.46, 25.81, 22.88, 21.67, 14.32. MS (ESI) calculated for
C60H71N3O10, m/z 993.51, found 1016.53 (M + Na)+.
Synthesis of Compound 18: 2-((R)-4-Amino-4-carboxybutanamido)-6-dodecanamido)
heptanedioic acid
The compound 17 (70 mg, 0.07 mmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the crude product which was purified using column
chromatography (50% MeOH/CH2Cl2) to obtain the compound 18 (32 mg, 92%). 1H NMR
(500 MHz, MeOD) δ 4.34 (s, 2H), 3.78 – 3.69 (m, 2H), 2.50 (t, J = 17.3 Hz, 2H), 2.23 (t, J =
7.4 Hz, 2H), 2.17 – 2.06 (m, 2H), 1.86 – 1.66 (m, 5H), 1.64 – 1.55 (m, 2H), 1.50 – 1.41 (d, J
= 15.2 Hz, 2H), 1.39 – 1.19 (m, 14H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz,
MeOD) δ 176.56, 53.81, 36.98, 33.24, 32.21, 30.92, 30.82, 30.64, 30.47, 27.13, 25.50,
23.90, 23.51, 14.59. MS (ESI) calculated for C24H43N3O8, m/z 501.31, found 502.32 (M +
H)+.
Synthesis of Compound 19: Dibenzyl 2-amino-6-((R)-5-(benzyloxy)-4-dodecanamido-5-
oxopentanamido)heptanedioate
The compound 15 (200 mg, 0.23 mmol) was dissolved in 10 mL of trifluoroacetic acid and
stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and drying
under vacuum to obtain the trifluoroacetate salt of compound 19 (203 mg, quantitative
yield). MS (ESI) calculated for C45H61N3O8, m/z 771.44, found 772.48 (M + H)+.
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Synthesis of Compound 20: 2-((R)-4-Carboxy-4-dodecanamidobutanamido)-6-
dodecanamidoheptanedioic acid
To a solution of 19 (50 mg, 56.4 μmol) in pyridine, were added lauroyl chloride (16.1 μL,
67.7 μmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 6 hours,
followed by evaporation of the solvent under reduced pressure. The residue was then
dissolved in dichloromethane and washed with water. The organic solvent was dried over
anhydrous sodium sulfate, filtered, evaporated under reduced pressure to obtain the crude
product. The crude was purified using column chromatography (35% EtOAc/hexanes) to
obtain the pure product, which was dissolved in methanol and subjected to catalytic
hydrogenolysis using Pd(OH)2/C at 60 psi hydrogen pressure for 2 hours, followed by
filtration through celite bed. The solvent was removed under reduced pressure to obtain the
compound 20 (34.3 mg, 89%). 1H NMR (500 MHz, MeOD) δ 4.45 – 4.25 (m, 3H), 2.34 (t, J
= 6.7 Hz, 2H), 2.28 – 2.07 (m, 5H), 1.98 – 1.79 (m, 3H), 1.70 (dd, J = 19.9, 14.8 Hz, 2H),
1.64 – 1.55 (m, 4H), 1.49 – 1.39 (m, 3H), 1.37 – 1.15 (m, 31H), 0.87 (t, J = 6.8 Hz, 6H). 13C
NMR (126 MHz, MeOD) δ 176.64, 175.98, 175.72, 175.21, 53.63, 36.99, 33.35, 33.25,
32.27, 30.92, 30.83, 30.65, 30.49, 28.88, 28.73, 27.10, 23.89, 23.54, 14.59. MS (ESI)
calculated for C36H65N3O9, m/z 683.47, found 682.49 (M – H)−.
Synthesis of Compound 21: (15R)-Tribenzyl 2,2-dimethyl-4,12-dioxo-3-oxa-5,11,16-
triazaoctacosane-6,10,15-tricarboxylate
To a solution of 14 (190 mg, 0.28 mmol) in anhydrous dichloromethane (10 mL) and
methanol (2 mL), were added dodecyl aldehyde (51.5 mg, 0.28 mmol), 3 – 4 drops of acetic
acid, and macroporous resin bound sodium cyanoborohydride (150 mg, 0.33 mmol). The
solution was stirred for 8 hours, followed by filtration to remove the resin. The solvent was
removed under vacuum to obtain the residue, which was purified using column
chromatography (15% EtOAc/hexanes) to obtain the compound 21 (124 mg, 51%). 1H
NMR (500 MHz, CDCl3) δ 7.43 – 7.27 (m, 15H), 5.25 – 5.09 (m, 6H), 4.50 (dd, J = 12.7,
7.7 Hz, 1H), 4.35 – 4.16 (m, 1H), 2.73 – 2.64 (m, 1H), 2.62 – 2.13 (m, 4H), 2.02 (t, J = 20.0
Hz, 1H), 1.91 – 1.72 (m, 3H), 1.71 – 1.50 (m, 4H), 1.41 (d, J = 12.6 Hz, 7H), 1.38 – 1.17
(m, 25H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.53, 172.11, 155.94,
155.65, 155.52, 135.36, 134.56, 130.91, 128.62, 128.43, 128.29, 79.94, 68.16, 67.97, 67.06,
60.40, 59.91, 53.22, 52.10, 47.94, 32.38, 32.20, 32.04, 31.95, 31.43, 30.99, 30.37, 29.64,
29.58, 29.36, 29.09, 28.92, 28.66, 28.34, 28.12, 27.43, 27.00, 23.76, 23.00, 22.72, 21.45,
21.24, 14.16. MS (ESI) calculated for C50H71N3O9, m/z 857.52, found 858.53 (M + H)+.
Synthesis of Compound 22: 2-Amino-6-((R)-4-carboxy-4-(dodecylamino)butanamido)
heptanedioic acid
The compound 21 (50 mg, 58.3 μmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 22 (35 mg,
quantitative yield in 2 steps). 1H NMR (500 MHz, MeOD) δ 4.40 (d, J = 3.5 Hz, 1H), 3.88 –
3.56 (m, 3H), 3.21 – 3.07 (m, 1H), 3.06 – 2.94 (m, 2H), 2.53 (t, J = 6.7 Hz, 2H), 2.14 (d, J =
6.0 Hz, 2H), 1.91 (s, 3H), 1.79 – 1.43 (m, 6H), 1.43 – 1.20 (m, 15H), 0.88 (t, J = 6.8 Hz,
3H). 13C NMR (126 MHz, MeOD) δ 175.33, 62.44, 62.15, 54.58, 53.37, 46.97, 46.32,
45.72, 45.40, 44.90, 33.10, 32.83, 32.34, 31.97, 31.13, 30.78, 30.68, 30.52, 30.24, 27.61,
27.46, 26.59, 26.28, 23.75, 23.09, 22.55, 22.34, 14.44. MS (ESI) calculated for
C24H45N3O7, m/z 487.33, found 488.34 (M + H)+.
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Synthesis of Compound 23: (15R)-Tribenzyl 2,2-dimethyl-16-octyl-4,12-dioxo-3-oxa-5,11,16-
triazatetracosane-6,10,15-tricarboxylate
To a solution of 14 (100 mg, 0.15 mmol) in anhydrous dichloromethane (10 mL) and
methanol (5 mL), were added octyl aldehyde (56.5 μL, 0.36 mmol), 3 – 4 drops of acetic
acid, and macroporous resin bound sodium cyanoborohydride (163.5 mg, 0.36 mmol). The
reaction mixture was then stirred for 10 hours, followed by filtration to remove the resin.
The solvent was removed under vacuum to obtain the compound 23 as crude. MS (ESI)
calculated for C54H79N3O9, m/z 913.58, found 914.60 (M + H)+.
Synthesis of Compound 24: (15R)-Tribenzyl 16-dodecyl-2,2-dimethyl-4,12-dioxo-3-
oxa-5,11,16- triazaoctacosane-6,10,15-tricarboxylate
To the solution of 14 (100 mg, 0.15 mmol) in anhydrous dichloromethane (10 mL) and
methanol (5 mL), were added dodecyl aldehyde (66.8 mg, 0.36 mmol), 3 – 4 drops of acetic
acid, and macroporous resin bound sodium cyanoborohydride (163.5 mg, 0.36 mmol). The
solution was then stirred for 14 hours, followed by filtration to remove the resin. The solvent
was removed under vacuum to obtain the residue, which was purified using column
chromatography (15% EtOAc/hexanes) to obtain the compound 24 (105 mg, 71%). 1H
NMR (500 MHz, CDCl3) δ 7.45 – 7.28 (m, 15H), 5.28 (dd, J = 12.0, 3.7 Hz, 1H), 5.23 –
5.01 (m, 6H), 4.44 (bs, 1H), 4.34 – 4.11 (m, 2H), 3.22 – 2.85 (m, 4H), 2.58 – 2.24 (m, 4H),
1.85 – 1.74 (m, 2H), 1.72 – 1.53 (m, 6H), 1.48 – 1.34 (m, 11H), 1.34 – 1.12 (m, 37H), 0.97 –
0.82 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 172.69, 172.23, 171.94, 171.40, 162.45,
135.64, 135.61, 134.64, 131.10, 129.21, 129.16, 129.03, 129.01, 128.92, 128.89, 128.82,
128.78, 128.62, 128.45, 128.38, 128.35, 80.10, 68.36, 68.11, 67.20, 63.20, 62.48, 53.51,
53.40, 52.72, 52.55, 38.92, 32.71, 32.12, 30.55, 29.82, 29.69, 29.63, 29.61, 29.54, 29.22,
29.20, 29.13, 28.51, 27.11, 24.94, 23.93, 23.20, 22.90, 21.88, 21.71, 14.34. MS (ESI)
calculated for C62H95N3O9, m/z 1025.71, found 1026.73 (M + H)+.
Synthesis of Compound 25: (15R)-Tribenzyl 16-hexadecyl-2,2-dimethyl-4,12-dioxo-3-oxa-
5,11,16-triazadotriacontane-6,10,15-tricarboxylate
To a solution of 14 (100 mg, 0.15 mmol) in anhydrous dichloromethane (10 mL) and
methanol (5 mL), were added hexadecanal (86.4 mg, 0.36 mmol), 3 – 4 drops of acetic acid,
and macroporous resin bound sodium cyanoborohydride (163.5 mg, 0.36 mmol). The
solution was then stirred for 14 hours, followed by filtration to remove the resin. The solvent
was removed under vacuum to obtain the residue, which was purified using column
chromatography (12% EtOAc/hexanes) to obtain the compound 25 (112 mg, 68%). 1H
NMR (500 MHz, CDCl3) δ 7.45 – 7.28 (m, 15H), 5.31 – 4.96 (m, 7H), 4.48 (d, J = 5.2 Hz,
1H), 4.26 – 4.18 (m, 1H), 3.24 – 2.06 (m, 9H), 1.77 – 1.55 (m, 8H), 1.46 – 1.33 (m, 11H),
1.33 – 1.07 (m, 53H), 0.88 (t, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 172.62,
172.24, 172.11, 171.63, 155.80, 155.69, 135.57, 131.10, 128.93, 128.83, 128.64, 128.57,
128.47, 128.41, 80.10, 68.36, 67.24, 67.18, 63.06, 62.51, 53.47, 53.37, 52.40, 52.14, 38.92,
32.82, 32.32, 32.14, 30.55, 29.92, 29.87, 29.86, 29.76, 29.74, 29.70, 29.58, 29.42, 29.36,
29.12, 28.51, 27.25, 25.07, 23.93, 23.19, 22.90, 21.78, 21.65, 14.34, 14.27. MS (ESI)
calculated for C70H111N3O9, m/z 1137.83, found 1138.85 (M + H)+.
Synthesis of Compound 26: 2-Amino-6-((R)-4-carboxy-4-(dioctylamino)butanamido)
heptanedioic acid
The crude of compound 23 was dissolved in methanol, followed by the addition of Pd(OH)2/
C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen pressure for 2
hours, followed by filtration through celite bed. The solvent was removed under reduced
pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic acid and
stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and drying
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under vacuum to obtain the residue which was further purified using column
chromatography to obtain the trifluoroacetate salt of compound 26 (60 mg, 64%). 1H NMR
(500 MHz, 10% CDCl3 in MeOD) δ 4.34 (dd, J = 9.2, 4.6 Hz, 1H), 3.91 – 3.79 (m, 2H),
3.21 – 3.00 (m, 4H), 2.51 (ddd, J = 29.4, 15.8, 6.3 Hz, 2H), 2.20 – 2.09 (m, 1H), 2.08 – 1.95
(m, 1H), 1.95 – 1.78 (m, 3H), 1.78 – 1.39 (m, 8H), 1.34 – 1.16 (m, 19H), 0.82 (t, J = 6.8 Hz,
6H). 13C NMR (126 MHz, 10% CDCl3 in MeOD) δ 175.14, 174.73, 174.41, 171.93, 53.92,
53.35, 33.09, 32.93, 32.48, 31.97, 31.09, 30.27, 30.21, 30.19, 27.71, 25.66, 23.75, 23.42,
22.53, 14.55. MS (ESI) calculated for C28H53N3O7, m/z 543.39, found 544.41 (M + H)+.
Synthesis of Compound 27: 2-Amino-6-((R)-4-carboxy-4-(didodecylamino)butanamido)
heptanedioic acid
The compound 24 (50 mg, 0.048 mmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 27 (37 mg,
quantitative yield). 1H NMR (500 MHz, MeOD) δ 4.43 – 4.37 (m, 1H), 3.87 (dd, J = 29.3,
7.5 Hz, 2H), 3.20 (dd, J = 19.5, 10.2 Hz, 2H), 3.15 – 3.05 (m, 2H), 2.73 – 2.46 (m, 3H), 2.27
– 1.99 (m, 3H), 1.98 – 1.83 (m, 3H), 1.72 (s, 5H), 1.63 – 1.43 (m, 3H), 1.31 (d, J = 38.3 Hz,
33H), 0.88 (t, J = 6.8 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 33.24, 30.92, 30.80, 30.69,
30.64, 30.34, 27.78, 23.90, 14.60. MS (ESI) calculated for C36H69N3O7, m/z 655.51, found
656.51 (M + H)+.
Synthesis of Compound 28: 2-Amino-6-((R)-4-carboxy-4-(dihexadecylamino)butanamido)
heptanedioic acid
The compound 25 (50 mg, 0.043 mmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 28 (38 mg,
quantitative yield). 1H NMR (500 MHz, 20% CDCl3 in MeOD) δ 4.48 – 4.20 (m, 2H), 3.86
– 3.73 (m, 3H), 3.29 – 3.04 (m, 4H), 2.72 – 2.44 (m, 3H), 2.31 – 1.80 (m, 7H), 1.80 – 1.48
(m, 8H), 1.46 – 1.12 (m, 46H), 0.89 (t, J = 6.9 Hz, 6H). 13C NMR (126 MHz, 20% CDCl3 in
MeOD) δ 31.40, 29.14, 29.11, 29.09, 29.04, 28.97, 28.94, 28.88, 28.82, 28.53, 26.03, 22.10,
13.07. MS (ESI) calculated for C44H85N3O7, m/z 767.64, found 768.65 (M + H)+.
Synthesis of Compound 30: (2R)-5-((4-(2-Amino-4-oxo-4,5-dihydro-1H-imidazol-5-yl)-1-
carboxybutyl)amino)-2-dodecanamido-5-oxopentanoic acid
To a solution of 19 (100 mg, 0.13 mmol) in pyridine, was added 1H-pyrazole-1-
carboxamidine.HCl (55.2 mg, 0.37 mmol). The reaction mixture was heated in microwave at
65 °C for 1 hour. The solvent was removed under vacuum and the residue was dissolved in
methanol, followed by the addition of Pd(OH)2/C. The solution was subjected to catalytic
hydrogenolysis at 60 psi hydrogen pressure for 2 hours, followed by filtration through celite
bed. The solvent was removed under reduced pressure to obtain the crude product which
was purified using column chromatography (30% MeOH/CH2Cl2) to obtain the compound
30 (38 mg, 58%). 1H NMR (500 MHz, MeOD) δ 4.40 – 4.27 (m, 2H), 4.21 – 4.18 (m, 1H),
2.34 (t, J = 5.9 Hz, 2H), 2.24 (dd, J = 13.3, 6.9 Hz, 2H), 2.20 – 1.95 (m, 2H), 1.95 – 1.65 (m,
5H), 1.64 – 1.54 (m, 2H), 1.54 – 1.43 (m, 2H), 1.37 – 1.21 (m, 15H), 0.88 (t, J = 6.8 Hz,
3H). 13C NMR (126 MHz, MeOD) δ 176.67, 176.56, 176.20, 175.20, 61.16, 54.19, 54.01,
53.67, 37.11, 37.03, 33.35, 33.25, 32.54, 32.46, 31.92, 31.80, 30.92, 30.81, 30.65, 30.51,
Agnihotri et al. Page 13













28.87, 27.09, 23.90, 22.56, 22.33, 22.19, 14.60. MS (ESI) calculated for C25H43N5O7, m/z
525.32, found 524.32 (M – H)−.
Synthesis of Compound 32: 2-((R)-4-Carboxy-4-dodecanamidobutanamido)-6-
guanidinoheptanedioic acid
To a solution of 19 (50 mg, 0.06 mmol) in THF, was added N,N′-di-Boc-1H-pyrazole-1-
carboxamidine.HCl (57.4 mg, 0.19 mmol) and pyridine (1 mL). The reaction mixture was
then stirred at 50 °C for 3 hours. The solvent was removed under reduced pressure and the
residue was dissolved in methanol, followed by the addition of Pd(OH)2/C. The solution
was subjected to catalytic hydrogenolysis at 60 psi hydrogen pressure for 1 hour, followed
by filtration through celite bed. The solvent was removed under reduced pressure to obtain
the crude, which was purified using column chromatography (8% MeOH/CH2Cl2). The
product was dissolved in 5 mL of trifluoroacetic acid and the reaction mixture was stirred
for 30 minutes, followed by removal of the solvent by purging nitrogen and drying under
vacuum to obtain the trifluoroacetate salt of the compound 32 (30 mg, 63%). 1H NMR (500
MHz, MeOD) δ 4.34 (s, 2H), 4.00 (s, 1H), 2.38 – 2.28 (m, 2H), 2.24 (dd, J = 14.4, 7.0 Hz,
2H), 2.18 – 2.08 (m, 1H), 2.07 – 1.80 (m, 4H), 1.79 – 1.65 (m, 2H), 1.61 – 1.55 (m, 2H),
1.55 – 1.36 (m, 3H), 1.36 – 1.19 (m, 14H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz,
5% CDCl3 in MeOD) δ 176.46, 175.71, 175.05, 158.34, 57.03, 54.25, 37.11, 33.35, 33.20,
33.11, 32.83, 32.64, 30.88, 30.78, 30.62, 30.51, 29.28, 27.06, 23.86, 22.90, 22.58, 14.59. MS
(ESI) calculated for C25H45N5O8, m/z 543.33, found 544.35 (M + H)+.
Synthesis of Compound 33: (6R)-6-Allyl 11,15-dibenzyl 2,2,19,19-tetramethyl-4,9,17-trioxo-
3,18-dioxa-5,10,16-triazaicosane-6,11,15-tricarboxylate
The compound 12 (250 mg, 0.29 mmol) was dissolved in 10 mL of dichloromethane,
followed by the addition of 3 mL of piperidine. The reaction mixture was stirred for 15
minutes, followed by removal of the solvent under reduced pressure. The residue was
dissolved in dichloromethane, followed by the addition of di-tert-butyl dicarbonate (95 mg,
0.43 mmol) and triethylamine (80 μL, 0.58 mmol). The reaction mixture was stirred at room
temperature for 1 hour, followed by removal of the solvent under reduced pressure. The
crude was purified using column chromatography (30% EtOAc/Hexanes) to obtain the
compound 33 (147 mg, 69%). 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.29 (m, 10H), 5.97 –
5.82 (m, 1H), 5.30 (ddd, J = 37.2, 23.6, 5.8 Hz, 3H), 5.21 – 5.06 (m, 5H), 4.68 – 4.51 (m,
3H), 4.38 – 4.20 (m, 2H), 2.31 (dd, J = 14.5, 7.3 Hz, 2H), 2.25 – 2.13 (m, 1H), 1.99 – 1.54
(m, 6H), 1.43 (s, J = 2.9 Hz, 20H). 13C NMR (126 MHz, CDCl3) δ 172.67, 172.58, 172.32,
172.18, 171.85, 156.06, 155.83, 135.55, 135.53, 135.47, 132.32, 132.24, 131.68, 128.83,
128.81, 128.69, 128.64, 128.61, 128.51, 128.46, 119.23, 119.13, 80.34, 80.17, 80.08, 77.48,
77.23, 76.98, 67.37, 67.27, 67.22, 67.18, 66.26, 53.34, 53.16, 53.04, 52.25, 52.18, 32.47,
32.24, 31.85, 31.76, 31.64, 29.88, 29.26, 29.01, 28.86, 28.50. MS (ESI) calculated for
C39H53N3O11, m/z 739.37, found 762.37 (M + Na)+.
Synthesis of Compound 34: (6R)-11,15-Dibenzyl 6-undecyl 2,2,19,19-tetramethyl-4,9,17-
trioxo- 3,18-dioxa-5,10,16-triazaicosane-6,11,15-tricarboxylate
To a solution of compound 33 (80 mg, 0.10 mmol) in ethanol:water (9:1), was added
Wilkinson’s catalyst (10 mg, 0.01 mmol). The reaction mixture was refluxed for 3 hours at
90 °C, followed by the removal of the solvent under reduced pressure. The crude was
purified using column chromatography (5% MeOH/CH2Cl2) and dried under vacuum. To
the solution of afforded product (52 mg, 0.07 mmol) in anhydrous DMF, were added 1-
undecanol (30 μL, 0.15 mmol), HBTU (33.7 mg, 0.09 mmol), triethylamine (20 μl, 0.15
mmol) and a catalytic amount of DMAP. The reaction mixture was stirred at room
temperature for 14 hours, followed by removal of the solvent under reduced pressure. The
residue was dissolved in ethyl acetate and washed with water. The organic fraction was
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dried over anhydrous sodium sulfate, filtered, concentrated and purified using column
chromatography (35% EtOAc/hexanes) to obtain the compound 34 (44.4 mg, 70%). 1H
NMR (500 MHz, CDCl3) δ 7.40 – 7.30 (m, 10H), 5.27 (dd, J = 22.5, 8.4 Hz, 1H), 5.20 –
4.96 (m, 5H), 4.65 – 4.49 (m, 1H), 4.41 – 4.20 (m, 2H), 4.16 – 4.07 (m, 2H), 2.30 (t, J = 6.8
Hz, 2H), 2.24 – 2.13 (m, 1H), 1.93 – 1.72 (m, 3H), 1.67- 1.59 (m, 3H), 1.43 (d, J = 2.7 Hz,
20H), 1.35 – 1.18 (m, 18H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
170.93, 170.59, 170.19, 154.13, 133.94, 127.20, 127.03, 126.85, 115.67, 78.69, 78.48,
65.63, 64.37, 51.77, 51.70, 51.47, 51.42, 50.64, 50.59, 30.87, 30.48, 30.17, 28.18, 28.07,
27.91, 27.82, 27.09, 26.90, 24.36, 21.27, 12.95. MS (ESI) calculated for C47H71N3O11, m/z
853.51, found 876.47 (M + Na)+.
Synthesis of Compound 35: 2-Amino-6-((R)-4-amino-5-oxo-5-(undecyloxy)pentanamido)
heptanedioic acid
The compound 34 (40 mg, 46.9 μmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 35 (32.8 mg,
quantitative yield). 1H NMR (500 MHz, CDCl3) δ 4.40 (dd, J = 9.2, 4.8 Hz, 1H), 4.32 – 4.22
(m, 2H), 4.11 (dd, J = 11.8, 6.0 Hz, 1H), 3.82 – 3.74 (m, 1H), 2.53 (t, J = 6.9 Hz, 2H), 2.23
(dt, J = 13.3, 6.7 Hz, 1H), 2.18 – 2.09 (m, 1H), 1.90 (ddd, J = 21.0, 13.9, 5.3 Hz, 3H), 1.80 –
1.67 (m, 3H), 1.64 – 1.46 (m, 2H), 1.43 – 1.22 (m, 16H), 0.91 (t, J = 6.9 Hz, 3H). 13C NMR
(126 MHz, CDCl3) δ 176.90, 172.93, 70.30, 57.13, 56.15, 56.04, 55.92, 55.86, 35.59, 34.66,
34.59, 33.84, 33.76, 33.26, 33.17, 32.99, 32.88, 32.08, 29.78, 29.71, 29.39, 26.26, 25.15,
24.95, 16.95. MS (ESI) calculated for C23H43N3O7, m/z 473.31, found 474.31 (M + H)+.
Synthesis of Compound 36: Dibenzyl 2-((tert-butoxycarbonyl)amino)-6-((R)-4-((tert-
butoxycarbonyl) amino)-5-oxo-5-(undecylamino)pentanamido)heptanedioate
To a solution of 33 (240 mg, 0.32 mmol) in ethanol:water (9:1), was added Wilkinson’s
catalyst (30 mg, 0.03 mmol). The reaction mixture was refluxed for 3 hours at 90 °C,
followed by removal of the solvent under reduced pressure. The crude was purified using
column chromatography (5% MeOH/CH2Cl2). To the solution of afforded product (193 mg,
0.27 mmol) in anhydrous dichloromethane, were added undecylamine (118 μL, 0.55 mmol),
HBTU (157 mg, 0.41 mmol), triethylamine (77 μl, 0.55 mmol) and a catalytic amount of
DMAP. The reaction mixture was stirred at room temperature for 14 hours, followed by
removal of the solvent under reduced pressure. The residue was dissolved in ethyl acetate
and washed with water. The organic fraction was dried over anhydrous sodium sulfate,
filtered, concentrated and purified using column chromatography (25% EtOAc/hexanes) to
obtain the compound 36 (188 mg, 81%). 1H NMR (500 MHz, CDCl3) δ 7.44 – 7.27 (m,
10H), 6.65 – 6.49 (m, 1H), 5.63 (d, J = 8.1 Hz, 1H), 5.62 – 5.52 (m, 1H), 5.23 – 4.92 (m,
5H), 4.60 – 4.45 (m, 2H), 4.27 (d, J = 8.2 Hz, 1H), 4.09 (d, J = 6.7 Hz, 1H), 3.31 – 3.14 (m,
2H), 2.38 – 2.22 (m, 1H), 2.00 – 1.53 (m, 5H), 1.49 – 1.32 (m, 23H), 1.31 – 1.21 (m, 16H),
0.90 – 0.84 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 174.07, 173.52, 172.99, 172.68,
171.76, 171.40, 157.18, 156.56, 135.51, 135.42, 128.88, 128.81, 128.74, 128.66, 128.59,
128.50, 128.38, 80.44, 80.17, 67.43, 67.28, 67.19, 53.47, 53.21, 52.65, 52.28, 39.89, 39.73,
32.98, 32.75, 32.47, 32.11, 31.96, 31.51, 30.67, 29.82, 29.76, 29.54, 28.53, 27.12, 22.89,
22.03, 21.87, 21.48, 21.35, 14.34. MS (ESI) calculated for C47H72N4O10, m/z 852.52, found
875.53 (M + Na)+.
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Synthesis of Compound 37: 2-Amino-6-((R)-4-amino-5-oxo-5-(undecylamino)pentanamido)
heptanedioic acid
The compound 36 (40 mg, 46.9 μmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 37 (32.8 mg,
quantitative yield). 1H NMR (500 MHz, MeOD) δ 4.47 – 4.32 (m, 1H), 3.92 – 3.79 (m, 1H),
3.64 – 3.54 (m, 1H), 3.28 – 3.13 (m, 2H), 2.56 – 2.34 (m, 2H), 2.19 – 2.01 (m, 2H), 2.00 –
1.60 (m, 4H), 1.58 – 1.41 (m, 4H), 1.30 (d, J = 21.4 Hz, 16H), 0.88 (t, J = 7.0 Hz, 3H). 13C
NMR (126 MHz, MeOD) δ 175.94, 175.78, 174.26, 174.03, 169.72, 55.49, 53.98, 53.77,
53.47, 40.75, 33.08, 32.29, 31.95, 31.82, 31.51, 31.31, 30.75, 30.46, 30.32, 28.74, 28.49,
28.04, 23.74, 22.62, 22.07, 14.44. MS (ESI) calculated for C23H44N4O6, m/z 472.33, found
473.33 (M + H)+.
Synthesis of Compound 38: (5R)-10,14-Dibenzyl 5-undecyl 1-(9H-fluoren-9-yl)-18,18-
dimethyl- 3,8,16-trioxo-2,17-dioxa-4,9,15-triazanonadecane-5,10,14-tricarboxylate
To a solution of 12 (100 mg, 0.11 mmol) in ethanol:water (9:1), was added Wilkinson’s
catalyst (10 mg, 0.01 mmol). The reaction mixture was refluxed for 3 hours at 90 °C,
followed by removal of the solvent under reduced pressure. The crude was purified using
column chromatography (5% MeOH/CH2Cl2) and dried under vacuum. To the solution of
afforded product (70 mg, 85.2 μmol) in anhydrous DMF, were added 1-undecanol (35 μL,
170 μmol), HBTU (38.8 mg, 102.2 μmol) and a catalytic amount of DMAP. The reaction
mixture was stirred at room temperature for 14 hours, followed by removal of the solvent
under reduced pressure. The crude was dissolved in ethyl acetate and washed with water.
The organic fraction was dried over anhydrous sodium sulfate, filtered, concentrated and
purified using column chromatography (15% EtOAc/hexanes) to obtain the compound 38
(63 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 6.4 Hz,
2H), 7.50 – 7.26 (m, 14H), 6.64 (s, 0.50H), 6.37 (s, 0.50H), 5.67 (dd, J = 32.4, 7.9 Hz, 1H),
5.21 – 4.99 (m, 5H), 4.62 – 4.53 (m, 1H), 4.47 – 4.31 (m, 3H), 4.30 – 4.19 (m, 2H), 4.13 (td,
J = 6.5, 2.6 Hz, 2H), 2.34 – 2.16 (m, 3H), 1.99 – 1.89 (m, 1H), 1.87 – 1.74 (m, 2H), 1.72 –
1.56 (m, 6H), 1.39 (d, J = 20.0 Hz, 10H), 1.33 – 1.20 (m, 15H), 0.90 (dt, J = 13.9, 7.3 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 172.77, 172.70, 172.64, 144.54, 144.29, 141.96,
135.98, 129.25, 129.14, 129.06, 128.95, 128.88, 128.36, 127.73, 125.79, 120.62, 80.57,
67.85, 67.75, 67.67, 66.58, 53.76, 52.66, 47.80, 32.91, 32.54, 32.19, 30.23, 30.13, 29.96,
29.85, 29.59, 29.13, 28.94, 26.41, 23.32, 21.58, 14.77. MS (ESI) calculated for
C57H73N3O11, m/z 975.52, found 998.46 (M + Na)+.
Synthesis of Compound 39: (5R)-10,14-Dibenzyl 5-ethyl 1-(9H-fluoren-9-yl)-18,18-dimethyl-
3,8,16-trioxo-2,17-dioxa-4,9,15-triazanonadecane-5,10,14-tricarboxylate
To a solution of 12 (100 mg, 0.11 mmol) in ethanol:water (9:1), was added Wilkinson’s
catalyst (10 mg, 0.01 mmol). The reaction mixture was refluxed for 3 hours at 90 °C,
followed by removal of the solvent under reduced pressure. The crude was purified using
column chromatography (5% MeOH/CH2Cl2) and dried under vacuum. To the solution of
afforded product (75 mg, 91.3 μmol) in anhydrous DMF, were added ethyl alcohol (11 μL,
182 μmol), HBTU (41.6 mg, 109.5 μmol) and a catalytic amount of DMAP. The reaction
mixture was stirred at room temperature for 14 hours, followed by removal of the solvent
under reduced pressure. The residue was dissolved in ethyl acetate and washed with water.
The organic fraction was dried over anhydrous sodium sulfate, filtered, concentrated and
purified using column chromatography (15% EtOAc/hexanes) to obtain the compound 39
(58.9 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 7.79 – 7.69 (m, 2H), 7.57 – 7.52 (m, 2H),
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7.57 – 7.26 (m, 14H), 6.61 (d, J = 6.9 Hz, 0.50H), 6.37 (t, J = 6.9 Hz, 0.50H), 5.65 (dd, J =
29.3, 7.3 Hz, 1H), 5.23 – 5.00 (m, 5H), 4.64 – 4.54 (m, 1H), 4.45 – 4.37 (m, 2H), 4.29 –
4.15 (m, 4H), 2.36 – 2.17 (m, 3H), 1.98 – 1.88 (m, 1H), 1.87 – 1.74 (m, 2H), 1.73 – 1.62 (m,
2H), 1.48 – 1.33 (m, 10H), 1.33 – 1.23 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 172.67,
172.18, 171.99, 156.58, 155.85, 144.11, 143.88, 141.52, 135.55, 135.46, 131.10, 129.00,
128.83, 128.71, 128.64, 128.53, 127.95, 127.31, 125.36, 120.20, 80.12, 68.37, 67.43, 67.24,
61.98, 53.55, 53.35, 52.22, 47.39, 38.92, 32.45, 31.79, 30.56, 29.12, 28.82, 28.52, 23.94,
23.20, 21.47, 21.29, 21.14, 14.36, 14.29, 11.17. MS (ESI) calculated for C48H55N3O11, m/z
849.38, found 872.37 (M + Na)+.
Synthesis of Compound 40: (15R)-10,6-Dibenzyl 15-undecyl 2,2-dimethyl-4,12,17-trioxo-3-
oxa- 5,11,16-triazaoctacosane-6,10,15-tricarboxylate
The compound 38 (50 mg, 0.05 mmol) was dissolved in 10 mL of dichloromethane,
followed by the addition of 3 mL of piperidine. The reaction mixture was stirred for 15
minutes, followed by removal of the solvent under reduced pressure. The residue (0.05
mmol) was dissolved in pyridine, followed by the addition of lauroyl chloride (14.6 μL, 0.06
mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 4 hours,
followed by evaporation of the solvent under reduced pressure. The residue was then
dissolved in dichloromethane and washed with water. The organic solvent was dried over
anhydrous sodium sulfate, filtered, evaporated under reduced pressure to obtain the crude
product which was purified using column chromatography (18% EtOAc/hexanes) to obtain
the compound 40 (36.4 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 7.74 – 7.29 (m, 10H),
7.18 – 7.06 (m, 1H), 6.59 – 6.41 (m, 2H), 5.31 – 5.08 (m, 5H), 4.73 – 4.63 (m, 1H), 4.54
(ddd, J = 12.1, 10.0, 5.6 Hz, 2H), 4.30 – 4.20 (m, 1H), 4.15 – 4.07 (m, 2H), 2.38 – 2.14 (m,
5H), 1.97 – 1.54 (m, 17H), 1.41 (d, J = 19.6 Hz, 7H), 1.34 – 1.19 (m, 26H), 0.98 – 0.81 (m,
6H). 13C NMR (126 MHz, CDCl3) δ 172.71, 172.50, 172.32, 172.18, 135.62, 128.86,
128.82, 128.65, 128.52, 128.46, 80.11, 67.31, 67.24, 66.15, 53.36, 52.27, 51.86, 36.87,
32.12, 29.82, 29.72, 29.56, 29.52, 29.44, 28.70, 28.55, 25.99, 25.90, 22.90, 14.34. MS (ESI)
calculated for C54H85N3O10, m/z 935.62, found 958.59 (M + Na)+.
Synthesis of Compound 41: 2-Amino-6-((R)-4-dodecanamido-5-oxo-5-(undecyloxy)
pentanamido)heptanedioic acid
The compound 40 (30 mg, 32.0 μmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 41 (24.6 mg,
quantitative yield). 1H NMR (500 MHz, CDCl3) δ 4.51 – 4.26 (m, 2H), 4.21 (ddd, J = 19.6,
10.9, 5.9 Hz, 1H), 4.15 – 3.95 (m, 2H), 2.51 – 2.13 (m, 4H), 2.12 – 1.48 (m, 21H), 1.48 –
1.38 (m, 2H), 1.37 – 1.05 (m, 21H), 0.96 – 0.80 (m, 6H). 13C NMR (126 MHz, CDCl3) δ
168.30, 68.63, 50.65, 50.48, 50.31, 50.14, 49.97, 39.16, 32.38, 30.79, 30.15, 29.86, 29.83,
29.37, 26.21, 24.17, 23.44, 23.14, 14.53, 14.51, 11.41. MS (ESI) calculated for
C35H65N3O8, m/z 655.48, found 654.51 (M – H+)−.
Synthesis of Compound 43: 2-Amino-6-((R)-4-guanidino-5-oxo-5-
(undecyloxy)pentanamido) heptanedioic acid
The compound 38 (50 mg, 0.05 mmol) was dissolved in 10 mL of dichloromethane,
followed by the addition of 3 mL of piperidine. The reaction mixture was stirred for 15
minutes, followed by removal of the solvent under reduced pressure. The crude mixture was
purified using column chromatography (5% MeOH/CH2Cl2) to obtain the free primary
amine derivative, which was dissolved in pyridine, followed by the addition of 1H-
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pyrazole-1-carboxamidine.HCl (22.2 mg, 0.15 mmol). The sealed reaction mixture was then
heated in microwave at 65 °C for 1 hour. The solvent was removed under vacuum and the
residue was dissolved in methanol, followed by the addition of Pd(OH)2/C. The solution
was subjected to catalytic hydrogenolysis at 60 psi hydrogen pressure for 4 hours, followed
by filtration through celite bed. The solvent was removed under reduced pressure to obtain
the crude product which was purified using column chromatography (30% MeOH/CH2Cl2)
to obtain the free carboxylic acid derivative, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 43 (20.3 mg, 47%
in 4 steps). 1H NMR (500 MHz, MeOD) δ 4.43 – 4.08 (m, 5H), 3.58 (bs, 1H), 2.46 – 2.27
(m, 3H), 2.12 – 1.90 (m, 2H), 1.84 (bs, 3H), 1.66 (dd, J = 13.7, 6.9 Hz, 2H), 1.53 – 1.41 (m,
2H), 1.40 – 1.19 (m, 15H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 67.16,
33.09, 30.76, 30.68, 30.49, 30.39, 29.66, 26.97, 23.75, 14.46. MS (ESI) calculated for
C24H45N5O7, m/z 515.33, found 516.31 (M + H)+.
Synthesis of Compound 44: (15R)-10,6-Dibenzyl 15-ethyl 2,2-dimethyl-4,12,17-trioxo-3-oxa-
5,11,16-triazaoctacosane-6,10,15-tricarboxylate
The compound 39 (100 mg, 0.11 mmol) was dissolved in 10 mL of dichloromethane,
followed by the addition of 3 mL of piperidine. The reaction mixture was stirred for 15
minutes, followed by removal of the solvent under reduced pressure to obtain the residue
which was dissolved in pyridine, followed by the addition of lauroyl chloride (41.9 μL, 0.18
mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 4 hours,
followed by evaporation of the solvent under reduced pressure. The residue was then
dissolved in dichloromethane and washed with water. The organic solvent was dried over
anhydrous sodium sulfate, filtered, evaporated under reduced pressure to obtain the crude
product which was purified using column chromatography (35% EtOAc/hexanes) to obtain
the compound 44 (65.4 mg, 69%). 1H NMR (500 MHz, CDCl3) δ 7.73 – 7.27 (m, 10H),
7.06 (dd, J = 17.7, 8.8 Hz, 1H), 6.65 – 6.53 (m, 1H), 6.47 – 6.36 (m, 1H), 5.20 – 5.05 (m,
4H), 4.53 – 4.50 (m, 3H), 4.33 – 4.09 (m, 4H), 2.35 – 2.11 (m, 5H), 1.93 – 1.69 (m, 4H),
1.68 – 1.65 (m, 3H), 1.47 – 1.33 (m, 9H), 1.32 – 1.17 (m, 18H), 0.92 – 0.83 (m, 3H). 13C
NMR (126 MHz, CDCl3) δ 172.42, 172.26, 135.58, 131.11, 129.02, 128.82, 128.65, 128.52,
128.47, 80.10, 68.37, 67.24, 61.95, 53.43, 52.32, 51.83, 38.93, 36.85, 32.12, 31.64, 30.56,
29.83, 29.71, 29.56, 29.51, 29.13, 28.55, 25.89, 23.94, 23.20, 22.91, 14.34, 14.28, 11.18. MS
(ESI) calculated for C45H67N3O10, m/z 809.48, found 832.51 (M + Na)+.
Synthesis of Compound 45: 2-Amino-6-((R)-4-dodecanamido-5-ethoxy-5-oxopentanamido)
heptanedioic acid
The compound 44 (30 mg, 37.0 μmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 45 (23.4 mg,
quantitative yield). 1H NMR (500 MHz, MeOD) δ 4.35 – 4.26 (m, 2H), 4.08 (qd, J = 7.1, 3.1
Hz, 2H), 3.73 (d, J = 11.0 Hz, 1H), 2.32 – 2.24 (m, 2H), 2.20 – 2.01 (m, 3H), 1.92 – 1.74
(m, 4H), 1.74 – 1.31 (m, 6H), 1.30 – 1.07 (m, 18H), 0.81 (dt, J = 13.9, 4.4 Hz, 3H). 13C
NMR (126 MHz, MeOD) δ 173.46, 62.57, 53.58, 53.23, 37.02, 36.92, 33.23, 33.13, 32.83,
31.46, 30.91, 30.82, 30.63, 30.46, 30.44, 28.53, 28.23, 27.18, 27.11, 23.89, 14.65, 14.59. MS
(ESI) calculated for C26H47N3O8, m/z 529.33, found 528.36 (M – H)−.
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Synthesis of Compound 46: Diethyl 2-((R)-4-amino-5-(benzyloxy)-5-oxopentanamido)-6-
((tert-butoxycarbonyl) amino)heptanedioate
The compound 13 (100 mg, 0.12 mmol) was dissolved in 10 mL of dichloromethane,
followed by the addition of 3 mL of piperidine. The reaction mixture was stirred for 15
minutes, followed by removal of the solvent under reduced pressure to obtain the crude
product which was purified using column chromatography (5% MeOH/CH2Cl2) to obtain
the compound 46 (66 mg, 92%). MS (ESI) calculated for C28H43N3O9, m/z 565.30, found
588.30 (M + Na)+.
Synthesis of Compound 48: Diethyl 2-amino-6-((R)-4-amino-5-oxo-5-(undecylthio)
pentanamido)heptanedioate
To a solution of compound 46 (50 mg, 0.08 mmol) in dichloromethane, were added di-tert-
butyl dicarbonate (28.9 mg, 0.13 mmol) and triethylamine (24.6 μl, 0.17 mmol). The
reaction mixture was stirred for 30 minutes, followed by complete removal of the solvent
under reduced pressure. The residue was dissolved in methanol, followed by the addition of
Pd(OH)2/C. The solution was then subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in anhydrous DMF,
followed by the addition of 1-undecanethiol (40 μL, 0.17 mmol), HBTU (40.2 mg, 0.10
mmol), triethylamine (24.7 μL, 0.17 mmol) and a catalytic amount of DMAP. The reaction
mixture was stirred at room temperature for 14 hours, followed by removal of the solvent
under reduced pressure. The residue was dissolved in ethyl acetate and washed with water.
The organic fraction was dried over anhydrous sodium sulfate, filtered, concentrated and
purified using column chromatography (30% EtOAc/hexanes) to obtain the compound 47
(41 mg, 63%). The compound 47 (40 mg, 0.05 mmol) was dissolved in 5 mL of
trifluoroacetic acid and stirred for 30 minutes, followed by removal of the solvent by
purging nitrogen and drying under vacuum to obtain the trifluoroacetate salt of the
compound 48 (41 mg, quantitative yield). 1H NMR (500 MHz, 20% CDCl3 in MeOD) δ
4.32 – 4.26 (m, 1H), 4.26 – 4.13 (m, 3H), 4.09 (q, J = 7.1 Hz, 2H), 3.91 (dt, , J = 2.0, 6.5 Hz,
1H), 2.95 (t, J = 7.3 Hz, 2H), 2.50 – 2.35 (m, 2H), 2.28 – 1.69 (m, 6H), 1.69 – 1.59 (m, 1H),
1.57 – 1.35 (m, 4H), 1.34 – 1.11 (m, 21H), 0.80 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz,
20% CDCl3 in MeOD) δ 197.50, 174.15, 63.80, 62.71, 62.66, 59.98, 53.86, 53.83, 53.78,
53.74, 33.18, 31.98, 31.79, 31.65, 31.19, 31.16, 30.84, 30.71, 30.58, 30.30, 29.94, 28.52,
28.44, 23.85, 22.77, 22.63, 14.64, 14.59, 14.56. MS (ESI) calculated for C27H51N3O6S, m/z
545.35, found 568.36 (M + Na)+.
Synthesis of Compound 50: (2R)-5-((6-Amino-1,7-diethoxy-1,7-dioxoheptan-2-yl)amino)-2-
dodecanamido-5-oxopentanoic acid
To a solution of 46 (36 mg, 0.06 mmol) in pyridine, were added lauroyl chloride (22.6 μL,
0.09 mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 4 hours,
followed by evaporation of the solvent under reduced pressure. The residue was then
dissolved in dichloromethane and washed with water. The organic solvent was dried over
anhydrous sodium sulfate, filtered, evaporated under reduced pressure to obtain the crude
product which was purified using column chromatography (18% EtOAc/hexanes) to obtain
the compound 49 (39.0 mg, 82%). The compound 49 (30 mg, 0.04 mmol) was dissolved in
methanol, followed by the addition of Pd(OH)2/C. The solution was subjected to catalytic
hydrogenolysis at 60 psi hydrogen pressure for 2 hours, followed by filtration through celite
bed. The solvent was removed under reduced pressure to obtain the residue, which was then
dissolved in 5 mL of trifluoroacetic acid and stirred for 30 minutes, followed by removal of
the solvent by purging nitrogen and drying under vacuum to obtain the trifluoroacetate salt
of the compound 50 (26.4 mg, quantitative yield in two steps). 1H NMR (500 MHz, MeOD)
δ 4.45 – 4.37 (m, 2H), 4.29 (q, J = 7.1 Hz, 2H), 4.16 (q, J = 6.6 Hz, 2H), 4.05 – 3.97 (m,
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1H), 2.34 (d, J = 2.6 Hz, 2H), 2.28 – 2.11 (m, 3H), 2.01 – 1.80 (m, 4H), 1.78 – 1.40 (m, 6H),
1.40 – 1.19 (m, 21H), 0.90 (dt, J = 13.6, 4.7 Hz, 3H). 13C NMR (126 MHz, MeOD) δ
176.49, 175.06, 174.90, 173.29, 170.44, 63.70, 62.49, 53.88, 53.80, 53.33, 53.13, 52.83,
49.52, 49.35, 49.18, 49.01, 48.84, 48.67, 48.50, 36.96, 36.87, 33.10, 32.79, 32.09, 32.04,
31.95, 31.02, 30.89, 30.78, 30.68, 30.51, 30.38, 28.84, 28.47, 27.01, 26.97, 23.76, 22.65,
22.42, 22.32, 14.44. MS (ESI) calculated for C28H51N3O8, m/z 557.37, found 558.40 (M +
H)+.
Synthesis of Compound 51: Dibenzyl 2-(4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)
butanamido)-6-((tert-butoxycarbonyl)amino)heptanedioate
To a solution of 9 (221 mg, 0.47 mmol) in anhydrous dichloromethane, were added 4-Fmoc-
amino-butyric acid (150 mg, 0.46 mmol), polystyrene bound carbodiimide (382.11 mg, 0.47
mmol) and a catalytic amount of polystyrene bound DMAP. The reaction mixture was
stirred at room temperature for 8 hours, followed by filtration to remove the solid resin. The
filtrate was evaporated under vacuum to obtain the residue which was then purified using
column chromatography (50% EtOAc/hexanes) to obtain the compound 51 (230 mg,
63%). 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.5 Hz, 2H), 7.57 (d, J = 7.4 Hz, 2H), 7.44
– 7.25 (m, 14H), 6.47 (d, J = 7.2 Hz, 1H), 5.21 – 5.00 (m, 6H), 4.61 – 4.50 (m, 1H), 4.46 –
4.33 (m, 2H), 4.31 – 4.15 (m, 2H), 3.29 – 3.11 (m, 2H), 2.26 – 2.12 (m, 2H), 1.76 (dd, J =
19.9, 6.1 Hz, 4H), 1.70 – 1.52 (m, 2H), 1.38 (d, J = 13.3 Hz, 11H). 13C NMR (126 MHz,
CDCl3) δ 172.70, 172.59, 172.45, 172.29, 157.10, 155.76, 144.15, 141.53, 135.54, 128.85,
128.82, 128.72, 128.64, 128.57, 128.45, 127.88, 127.25, 125.28, 120.16, 80.19, 67.42,
67.34, 67.24, 66.76, 53.34, 52.18, 47.49, 40.21, 33.33, 32.45, 32.30, 31.65, 28.53, 26.21,
21.59, 21.28. MS (ESI) calculated for C45H51N3O9, m/z 777.36, found 800.33 (M + Na)+.
Synthesis of Compound 52: Dibenzyl 2-((tert-butoxycarbonyl)amino)-6-(4-
dodecanamidobutanamido) heptanedioate
The compound 51 (140 mg, 0.18 mmol) was dissolved in 10 mL of dichloromethane,
followed by the addition of 3 mL of piperidine. The reaction mixture was stirred for 15
minutes, followed by removal of the solvent under reduced pressure to obtain the residue
which was dissolved in pyridine, followed by the addition of lauroyl chloride (64.0 μL, 0.27
mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 4 hours,
followed by evaporation of the solvent under reduced pressure. The residue was then
dissolved in dichloromethane and washed with water. The organic solvent was dried over
anhydrous sodium sulfate, filtered, evaporated under reduced pressure to obtain the crude
product which was purified using column chromatography (30% EtOAc/hexanes) to obtain
the compound 52 (100 mg, 75%). 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.29 (m, 10H), 6.84
– 6.76 (m, 1H), 5.97 – 5.88 (m, 1H), 5.26 – 5.09 (m, 5H), 4.59 – 4.50 (m, 1H), 4.26 (d, J =
8.5 Hz, 1H), 3.40 – 3.30 (m, 1H), 3.25 – 3.17 (m, 1H), 2.29 – 2.22 (m, 2H), 2.17 – 2.14 (m,
2H), 1.87 – 1.76 (m, 4H), 1.66 (s, 4H), 1.63 – 1.58 (m, 2H), 1.42 (d, J = 14.4 Hz, 9H), 1.33
– 1.20 (m, 16H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.14, 173.13,
172.73, 172.62, 172.43, 172.27, 155.92, 155.80, 135.57, 128.84, 128.69, 128.65, 128.56,
128.46, 80.12, 67.27, 53.39, 52.34, 38.80, 37.10, 33.62, 32.30, 32.12, 31.57, 29.84, 29.82,
29.72, 29.57, 29.55, 28.55, 26.06, 25.93, 22.90, 21.66, 21.34, 14.34. MS (ESI) calculated for
C42H63N3O8, m/z 737.46, found 760.41 (M + Na)+.
Synthesis of Compound 53: 2-Amino-6-(4-dodecanamidobutanamido)heptanedioic acid
The compound 52 (50 mg, 0.06 mmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
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drying under vacuum to obtain the trifluoroacetate salt of the compound 53 (38 mg,
quantitative yield). 1H NMR (500 MHz, MeOD) δ 4.39 (dd, J = 9.3, 4.7 Hz, 1H), 3.80 –
3.73 (m, 1H), 3.20 (t, J = 7.0 Hz, 2H), 2.32 – 2.24 (m, 2H), 2.21 – 2.14 (m, 2H), 2.00 – 1.68
(m, 7H), 1.66 – 1.42 (m, 5H), 1.36 – 1.24 (m, 14H), 0.90 (dd, J = 13.1, 6.2 Hz, 3H). 13C
NMR (126 MHz, MeOD) δ 176.66, 175.79, 175.46, 173.04, 54.83, 53.43, 39.81, 37.36,
34.18, 33.23, 32.45, 32.39, 31.61, 31.48, 30.90, 30.80, 30.63, 30.52, 27.24, 26.85, 23.89,
23.07, 22.75, 14.58. MS (ESI) calculated for C23H43N3O6, m/z 457.32, found 458.39 (M +
H)+.
Synthesis of Compound 54: 5-((1,7-Bis(benzyloxy)-6-((tert-butoxycarbonyl)amino)-1,7-
dioxoheptan-2-yl)amino)-5-oxopentanoic acid
To a solution of 9 (100 mg, 0.21 mmol) in anhydrous dichloromethane, was added glutaric
anhydride (25.5 mg, 0.22 mmol). The reaction mixture was stirred at room temperature for 1
hour, followed by removal of the solvent under reduced pressure. The residue was then
purified using column chromatography (5% MeOH/CH2Cl2) to obtain the compound 54
(118 mg, 95%). 1H NMR (500 MHz, CDCl3) δ 7.73 – 7.29 (m, 10H), 6.87 – 6.34 (m, 1H),
5.22 – 5.08 (m, 4H), 4.60 (bs, 1H), 4.32 – 3.92 (m, 1H), 2.54 – 2.17 (m, 4H), 2.13 – 1.54 (m,
6H), 1.52 – 1.20 (m, 13H). 13C NMR (126 MHz, CDCl3) δ 176.46, 172.80, 172.69, 172.41,
135.41, 131.11, 129.01, 128.86, 128.84, 128.74, 128.69, 128.54, 80.46, 68.37, 67.51, 67.43,
67.15, 53.35, 52.10, 51.82, 38.92, 35.67, 35.08, 33.61, 33.49, 32.99, 32.44, 31.80, 31.66,
31.00, 30.55, 29.91, 29.13, 28.53, 28.31, 23.93, 23.20, 21.55, 21.21, 20.61, 19.92. MS (ESI)
calculated for C31H40N2O9, m/z 584.27, found 607.26 (M + Na)+.
Synthesis of Compound 55: Dibenzyl 2-((tert-butoxycarbonyl)amino)-6-(5-oxo-5-
(undecyloxy) pentanamido)heptanedioate
To a solution of 54 (90 mg, 0.15 mmol) in anhydrous DMF, were added 1- undecanol (63
μL, 0.30 mmol), HBTU (70 mg, 0.18 mmol), triethylamine (43 μL, 0.30 mmol) and a
catalytic amount of DMAP. The reaction mixture was stirred at room temperature for 12
hours, followed by removal of the solvent under reduced pressure. The residue was
dissolved in ethylacetate and washed with water. The organic fraction was dried over
anhydrous sodium sulfate, filtered, concentrated and purified using column chromatography
(10% EtOAc/hexanes) to obtain the compound 55 (86.4 mg, 78%).1H NMR (500 MHz,
CDCl3) δ 7.40 – 7.29 (m, 10H), 6.15 (d, J = 6.3 Hz, 1H), 5.20 – 5.02 (m, 5H), 4.62 – 4.54
(m, 1H), 4.32 – 4.19 (m, 1H), 4.05 (t, J = 6.8 Hz, 2H), 2.40 – 2.32 (m, 2H), 2.30 – 2.22 (m,
2H), 2.00 – 1.90 (m, 2H), 1.87 – 1.57 (m, 7H), 1.43 (s, 9H), 1.33 – 1.19 (m, 17H), 0.88 (t, J
= 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.49, 173.48, 172.70, 172.57, 172.42,
172.27, 172.26, 155.85, 155.70, 135.55, 135.42, 128.86, 128.82, 128.73, 128.66, 128.55,
128.47, 80.20, 80.09, 67.43, 67.35, 67.25, 64.90, 53.31, 52.03, 51.99, 35.39, 33.47, 32.49,
32.26, 32.11, 31.96, 31.84, 29.80, 29.79, 29.73, 29.54, 29.47, 28.82, 28.52, 26.11, 22.89,
21.48, 21.20, 20.97, 14.33. MS (ESI) calculated for C42H62N2O9, m/z 738.45, found 761.43
(M + Na)+.
Synthesis of Compound 56: 2-Amino-6-(5-oxo-5-(undecyloxy)pentanamido)heptanedioic
acid
The compound 55 (35 mg, 0.04 mmol) was dissolved in methanol, followed by the addition
of Pd(OH)2/C. The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen
pressure for 2 hours, followed by filtration through celite bed. The solvent was removed
under reduced pressure to obtain the residue, which was dissolved in 5 mL of trifluoroacetic
acid and stirred for 30 minutes, followed by removal of the solvent by purging nitrogen and
drying under vacuum to obtain the trifluoroacetate salt of the compound 56 (26 mg,
quantitative yield). 1H NMR (500 MHz, MeOD) δ 4.34 (dd, J = 8.7, 5.0 Hz, 1H), 4.02 (t, J =
6.7 Hz, 2H), 3.82 – 3.73 (m, 1H), 2.34 (t, J = 7.5 Hz, 2H), 2.27 (t, J = 7.2 Hz, 2H), 1.97 –
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1.80 (m, 5H), 1.74 – 1.63 (m, 1H), 1.62 – 1.42 (m, 4H), 1.29 – 1.25 (m, 16H), 0.86 (t, J =
6.9 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 175.63, 175.60, 175.35, 175.32, 175.12,
172.76, 65.83, 54.68, 54.54, 53.40, 53.36, 35.86, 34.37, 33.19, 32.40, 32.32, 31.51, 31.39,
30.85, 30.84, 30.78, 30.59, 30.51, 29.86, 27.16, 23.86, 22.99, 22.73, 22.27, 14.60. MS (ESI)
calculated for C23H42N2O7, m/z 458.30, found 459.32 (M + H)+.
General procedure for the syntheses of compounds (66–79)
Synthesis of compound 66: Dibenzyl 2-((R)-4-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-5- (benzyloxy)-5-oxopentanamido)heptanedioate: To a
solution of 4 (100 mg, 0.21 mmol) in dichloromethane, were added 58 (78.8 mg, 0.22
mmol), polystyrene bound carbodiimide (170 mg, 0.22 mmol), triethylamine (60 μL, 0.43
mmol) and a catalytic amount of polystyrene bound DMAP. The reaction mixture was
stirred at room temperature for 8 hours, followed by filtration to remove the solid resin. The
filtrate was evaporated under vacuum to obtain the residue which was then purified using
column chromatography (55% EtOAc/hexanes) to obtain the compound 66 (154 mg,
89%). 1H NMR (500 MHz, CDCl3,) δ 7.74 (d, J = 7.5 Hz, 2H), 7.57 (d, J = 7.0 Hz, 2H),
7.41 – 7.24 (m, 19H), 6.47 (d, J = 7.8 Hz, 0.50H), 6.19 (d, J = 7.8 Hz, 0.50H), 5.67 (dd, J =
20.4, 8.0 Hz, 1H), 5.20 – 5.03 (m, 6H), 4.59 (ddd, J = 13.0, 7.5, 5.3 Hz, 1H), 4.49 – 4.33 (m,
3H), 4.18 (t, J = 6.8 Hz, 1H), 2.27 – 2.19 (m, 5H), 2.02 – 1.77 (m, 3H), 1.63 – 1.61 (m, 1H),
1.38 – 1.16 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 173.17, 171.06, 170.13, 170.04,
169.40, 153.91, 141.79, 141.42, 139.22, 133.04, 126.56, 126.55, 126.53, 126.51, 126.46,
126.31, 126.24, 126.21, 126.13, 126.09, 125.63, 125.00, 123.03, 117.90, 65.30, 65.07,
64.95, 64.08, 51.35, 50.01, 45.06, 31.74, 29.88, 26.66, 26.14, 22.55, 22.27. MS (ESI)
calculated for C48H48N2O9, m/z 796.34, found 819.31 (M + Na)+.
Synthesis of compound 67: 2-((R)-4-carboxy-4-dodecanamidobutanamido)heptanedioic
acid: The compound 66 (147 mg, 0.18 mmol) was dissolved in 10 mL of dichloromethane,
followed by the addition of 3 mL of piperidine. The reaction mixture was stirred for 15
minutes, followed by removal of the solvent under reduced pressure to obtain the residue,
which was dissolved in pyridine, followed by the addition of lauroyl chloride (64.0 μL, 0.27
mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 4 hours,
followed by evaporation of the solvent under reduced pressure. The residue was then
dissolved in dichloromethane and washed with water. The organic solvent was dried over
anhydrous sodium sulfate, filtered, evaporated under reduced pressure to obtain the crude
product which was purified using column chromatography (25% EtOAc/hexanes) to obtain
the protected intermediate of compound 67 (100 mg, 73%). The protected intermediate (50
mg, 0. 06 mmol) was then dissolved in methanol, followed by the addition of Pd(OH)2/C.
The solution was subjected to catalytic hydrogenolysis at 60 psi hydrogen pressure for 2
hours, followed by filtration through celite bed. The solvent was removed under reduced
pressure to obtain the compound 67 (29 mg, quantitative yield). 1H NMR (500 MHz,
MeOD) δ 4.42 – 4.28 (m, 2H), 2.33 (t, J = 6.8 Hz, 2H), 2.28 (t, J = 7.4 Hz, 2H), 2.24 – 2.18
(m, 2H), 2.18 – 2.10 (m, 1H), 1.93 (dt, J = 13.8, 6.3 Hz, 1H), 1.85 – 1.82 (m, 1H), 1.72 –
1.54 (m, 5H), 1.41 (dd, J = 14.5, 7.4 Hz, 3H), 1.30 – 1.26 (m, 15H), 0.87 (t, J = 6.9 Hz,
3H). 13C NMR (126 MHz, MeOD) δ 177.59, 176.63, 176.63, 175.03, 54.04, 53.66, 37.03,
34.85, 33.36, 33.24, 32.50, 32.45, 30.91, 30.81, 30.64, 30.48, 28.97, 28.79, 27.07, 26.66,
25.78, 23.90, 14.60. MS (ESI) calculated for C24H42N2O8, m/z 486.29, found 485.29 (M –
H)−.
In the case of N-Boc protected intermediates (compound 68, 72, 76, 78), the compound after
hydrogenolysis was dissolved in trifluoroacetic acid and stirred for 30 minutes, followed by
removal of the solvent by purging nitrogen and drying under vacuum to obtain the
trifluoroacetate salt of the compound 69, 73, 77, 79.
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Synthesis of compound 68: (R)-Benzyl 2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-5-((5- ((tert-butoxycarbonyl)amino)pentyl)amino)-5-
oxopentanoate: 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H), 7.71 (dt, J = 7.3,
3.6 Hz, 1H), 7.61 (t, J = 6.8 Hz, 2H), 7.54 (dd, J = 5.7, 3.3 Hz, 1H), 7.40 (t, J = 7.5 Hz, 2H),
7.37 – 7.30 (m, 5H), 5.18 (q, J = 12.1 Hz, 2H), 4.46 – 4.32 (m, 3H), 4.25 – 4.17 (m, 2H),
3.42 (dd, J = 5.5, 3.9 Hz, 1H), 3.18 (ddd, J = 20.5, 13.5, 7.0 Hz, 2H), 3.07 (s, 2H), 2.20 –
2.18 (m, 3H), 1.52 – 1.38 (m, 10H), 1.37 – 1.27 (m, 7H). 13C NMR (126 MHz, CDCl3) δ
168.20, 141.65, 135.35, 131.45, 129.30, 129.14, 129.03, 128.87, 128.24, 127.59, 125.59,
120.48, 79.88, 68.70, 67.86, 50.32, 50.15, 49.98, 47.61, 39.76, 39.20, 30.83, 30.05, 29.41,
28.88, 24.34, 24.21, 23.47. MS (ESI) calculated for C37H45N3O7, m/z 643.33, found 666.34
(M + Na)+.
Synthesis of compound 69: (R)-5-((5-Aminopentyl)amino)-2-dodecanamido-5-
oxopentanoic acid: 1H NMR (400 MHz, MeOD) δ 4.21 (dd, J = 8.4, 4.9 Hz, 1H), 3.30 –
3.18 (m, 2H), 2.92 (t, J = 6.7 Hz, 2H), 2.27 – 2.20 (m, 4H), 2.08 (td, J = 13.5, 6.5 Hz, 1H),
1.94 (td, J = 13.6, 7.3 Hz, 1H), 1.72 – 1.39 (m, 8H), 1.37 – 1.20 (m, 16H), 0.88 (dd, J =
12.0, 5.4 Hz, 3H). 13C NMR (101 MHz, 10% CDCl3 in MeOD) δ 174.03, 53.83, 38.93,
37.98, 36.02, 32.27, 31.46, 29.16, 29.04, 28.87, 27.91, 26.29, 25.40, 22.64, 22.17, 13.26. MS
(ESI) calculated for C22H43N3O4, m/z 413.33, found 414.37(M+H)+.
Synthesis of compound 70: (2R)-Benzyl 2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-5-oxo- 5-((2-oxoazepan-3-yl)amino)pentanoate: 1H NMR
(500 MHz, CDCl3, Ethyl Acetate) δ 7.76 (d, J = 7.5 Hz, 2H), 7.61 (d, J = 7.4 Hz, 2H), 7.35
(qd, J = 14.7, 7.3 Hz, 9H), 6.98 – 6.90 (m, 1H), 6.06 (bs, 1H), 5.88 – 5.81 (m, 1H), 5.23 –
5.13 (m, 2H), 4.54 – 4.48 (m, 1H), 4.46 – 4.33 (m, 3H), 4.21 (t, J = 7.1 Hz, 1H), 3.30 – 3.18
(m, 2H), 2.37 – 2.18 (m, 3H), 1.99 – 1.97 (m, 1H), 1.84 – 1.76 (dd, J = 14.6, 9.4 Hz, 1H),
1.62 (bs, 3H), 1.49 – 1.35 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 175.57, 172.14, 171.16,
156.34, 144.15, 143.99, 141.49, 135.45, 128.85, 128.71, 128.54, 127.90, 127.30, 125.43,
120.17, 67.51, 67.29, 53.98, 53.91, 52.46, 47.38, 42.38, 32.37, 32.32, 31.76, 31.70, 29.05,
28.10, 27.98, 27.93. MS (ESI) calculated for C33H35N3O6, m/z 569.25, found 592.23 (M +
Na)+.
Synthesis of compound 71: (2R)-2-Dodecanamido-5-oxo-5-((2-oxoazepan-3-
yl)amino)pentanoic acid: 1H NMR (500 MHz, MeOD) δ 4.54 (dd, J = 11.4, 1.5 Hz, 1H),
4.41 – 4.31 (m, 1H), 3.30 – 3.13 (m, 3H), 2.34 (tt, J = 6.4, 5.0 Hz, 2H), 2.27 – 2.11 (m, 3H),
2.02 – 1.72 (m, 5H), 1.65 – 1.49 (m, 3H), 1.43 – 1.22 (m, 16H), 0.88 (t, J = 7.0 Hz, 3H). 13C
NMR (126 MHz, MeOD) δ 177.24, 176.35, 176.30, 174.12, 174.02, 53.35, 49.46, 49.29,
42.47, 36.94, 33.37, 33.27, 33.10, 32.21, 32.16, 30.78, 30.77, 30.67, 30.51, 30.50, 30.36,
29.94, 29.16, 28.87, 28.80, 26.92, 23.75, 14.45. MS (ESI) calculated for C23H41N3O5, m/z
439.30, found 462.31 (M + Na)+.
Synthesis of compound 72: (R)-Benzyl 2-((R)-4-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)- 5-(benzyloxy)-5-oxopentanamido)-6-((tert-
butoxycarbonyl)amino)hexanoate: 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz,
2H), 7.60 (d, J = 7.2 Hz, 2H), 7.45 – 7.28 (m, 14H), 6.32 (d, J = 6.9 Hz, 1H), 5.71 (d, J = 8.0
Hz, 1H), 5.22 – 5.08 (m, 4H), 4.59 (t, J = 10.9 Hz, 2H), 4.40 (d, J = 6.9 Hz, 3H), 4.20 (t, J =
6.9 Hz, 1H), 3.02 (bs, 2H), 2.24 (s, 3H), 1.95 (dd, J = 15.4, 7.9 Hz, 1H), 1.83 (ddd, J = 15.7,
10.6, 5.3 Hz, 1H), 1.67 (d, J = 8.6 Hz, 1H), 1.41 (s, 11H), 1.36 – 1.23 (m, 2H). 13C NMR
(126 MHz, CDCl3) δ 172.37, 172.01, 171.81, 156.51, 156.28, 144.10, 143.86, 141.53,
135.48, 135.36, 128.87, 128.84, 128.78, 128.73, 128.63, 128.56, 127.94, 127.31, 125.34,
120.20, 120.18, 79.31, 67.61, 67.36, 67.27, 53.63, 52.36, 47.37, 40.17, 32.26, 32.02, 29.71,
28.62, 22.50. MS (ESI) calculated for C45H51N3O9, m/z 777.36, found 800.35 (M + Na)+.
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Synthesis of compound 73: (R)-6-Amino-2-((R)-4-carboxy-4-
dodecanamidobutanamido) hexanoic acid: 1H NMR (500 MHz, MeOD) δ 4.31 (dd, J =
9.1, 4.4 Hz, 1H), 4.26 (dd, J = 9.6, 4.3 Hz, 1H), 2.89 – 2.79 (m, 2H), 2.26 (t, J = 7.2 Hz,
2H), 2.21 – 2.08 (m, 3H), 1.88 – 1.75 (m, 2H), 1.68 – 1.48 (m, 5H), 1.47 – 1.08 (m, 18H),
0.80 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 176.55, 174.81, 53.42, 53.24,
40.56, 36.97, 33.10, 33.04, 32.34, 30.79, 30.77, 30.68, 30.52, 30.50, 30.38, 28.64, 27.95,
27.00, 23.78, 23.75, 14.45. MS (ESI) calculated for C23H43N3O6, m/z 457.32, found 458.33
(M + H)+.
Synthesis of compound 74: (R)-Benzyl 6-((R)-4-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)- 5-(benzyloxy)-5-oxopentanamido)-2-
(((benzyloxy)carbonyl)amino)hexanoate: 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.5
Hz, 2H), 7.61 – 7.52 (m, 2H), 7.38 – 7.25 (m, 19H), 5.80 (bs, 1H), 5.71 (d, J = 7.8 Hz, 1H),
5.45 – 5.41 (m, 1H), 5.19 – 5.09 (m, 4H), 5.06 (s, 2H), 4.44 – 4.30 (m, 4H), 4.16 (t, J = 6.8
Hz, 1H), 3.14 (dt, J = 13.8, 6.8 Hz, 2H), 2.17 – 2.11 (m, 3H), 1.93 (dd, J = 17.2, 11.2 Hz,
1H), 1.80 (dt, J = 10.2, 7.3 Hz, 1H), 1.70 – 1.62 (m, 1H), 1.49 – 1.38 (m, 2H), 1.33 – 1.24
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 172.41, 172.02, 156.59, 156.24, 144.10, 143.81,
141.53, 141.48, 136.40, 135.46, 135.37, 128.86, 128.84, 128.74, 128.72, 128.62, 128.53,
128.41, 128.30, 127.94, 127.29, 125.35, 125.31, 120.20, 67.58, 67.37, 67.28, 67.20, 53.88,
53.75, 47.34, 39.29, 32.59, 32.34, 29.00, 28.82, 22.53. MS (ESI) calculated for
C48H49N3O9, m/z 811.35, found 834.34 (M + Na)+.
Synthesis of compound 75: (R)-2-Amino-6-((R)-4-carboxy-4-
dodecanamidobutanamido) hexanoic acid: 1H NMR (500 MHz, MeOD) δ 4.34 (dd, J =
9.1, 4.9 Hz, 1H), 3.80 (t, J = 6.1 Hz, 1H), 3.22 (dt, J = 13.3, 6.7 Hz, 1H), 3.13 (dt, J = 13.5,
6.7 Hz, 1H), 2.30 – 2.12 (m, 5H), 1.97 – 1.79 (m, 3H), 1.64 – 1.56 (m, 2H), 1.52 (dd, J =
13.8, 6.7 Hz, 2H), 1.49 – 1.39 (m, 2H), 1.30 – 1.26 (d, J = 17.6 Hz, 16H), 0.87 (t, J = 6.9
Hz, 3H). 13C NMR (126 MHz, MeOD) δ 176.53, 174.85, 54.57, 53.08, 39.85, 36.89, 33.27,
33.10, 31.40, 30.78, 30.68, 30.52, 30.50, 30.34, 30.00, 28.69, 26.96, 23.76, 23.40, 14.46. MS
(ESI) calculated for C23H43N3O6, m/z 457.32, found 456.33 (M – H)−.
Synthesis of compound 76: (S)-Tert-butyl 2-((R)-4-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-5-(benzyloxy)-5-oxopentanamido)-6-
(((benzyloxy)carbonyl)amino) hexanoate: 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.5
Hz, 2H), 7.61 – 7.54 (m, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.35 – 7.25 (m, 12H), 6.30 (dd, J =
84.8, 7.6 Hz, 1H), 5.74 (dd, J = 17.5, 7.9 Hz, 1H), 5.14 (t, J = 12.2 Hz, 2H), 5.08 – 5.01 (m,
2H), 4.88 (bs, 1H), 4.42 – 4.30 (ddt, J = 31.5, 17.9, 7.6 Hz, 4H), 4.17 (t, J = 6.8 Hz, 1H),
3.14 (dd, J = 12.7, 6.4 Hz, 2H), 2.31 – 2.13 (m, 3H), 1.98 (dd, J = 14.5, 7.7 Hz, 1H), 1.76
(ddd, J = 15.5, 10.2, 5.3 Hz, 1H), 1.64 – 1.61 (m, 1H), 1.51 – 1.44 (m, 2H), 1.44 – 1.42 (m,
9H), 1.37 – 1.27 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 172.11, 171.84, 171.77, 156.72,
156.51, 144.12, 143.85, 141.50, 136.79, 135.36, 128.85, 128.73, 128.70, 128.57, 128.28,
127.92, 127.30, 125.35, 120.19, 120.17, 82.33, 67.57, 67.31, 66.76, 53.67, 52.76, 47.34,
40.77, 32.41, 32.16, 29.58, 28.70, 28.19, 22.29. MS (ESI) calculated for C45H51N3O9, m/z
777.36, found 800.36 (M + Na)+.
Synthesis of compound 77: (S)-6-Amino-2-((R)-4-carboxy-4-
dodecanamidobutanamido) hexanoic acid: 1H NMR (500 MHz, MeOD) δ 4.35 (bs, 2H),
2.91 (t, J = 7.4 Hz, 2H), 2.32 (t, J = 6.7 Hz, 2H), 2.22 (t, J = 7.5 Hz, 2H), 2.17 – 2.08 (m,
1H), 1.96 – 1.87 (m, 2H), 1.77 – 1.55 (m, 5H), 1.48 (dd, J = 15.2, 7.6 Hz, 2H), 1.30 – 1.27
(m, 16H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 176.53, 175.19, 53.81,
40.68, 37.07, 33.41, 33.23, 32.47, 32.36, 30.92, 30.81, 30.65, 30.50, 29.17, 28.86, 28.12,
27.10, 23.95, 23.89, 14.60. MS (ESI) calculated for C23H43N3O6, m/z 457.32, found 458.32
(M + H)+.
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Synthesis of compound 78: (S)-Tert-butyl 6-((R)-4-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-5-(benzyloxy)-5-oxopentanamido)-2-((tert-
butoxycarbonyl)amino) hexanoate: 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.5 Hz,
2H), 7.61 – 7.55 (m, 2H), 7.41 – 7.25 (m, 9H), 5.89 (bs, 1H), 5.78 (d, J = 7.9 Hz, 1H), 5.16
(q, J = 12.2 Hz, 2H), 5.07 (d, J = 8.1 Hz, 1H), 4.37 (ddd, J = 28.8, 10.6, 7.1 Hz, 3H), 4.19 (t,
J = 7.0 Hz, 1H), 3.19 (ddt, J = 25.6, 13.1, 6.5 Hz, 2H), 2.18 (t, J = 10.6 Hz, 2H), 2.01 – 1.92
(m, 1H), 1.78 – 1.62 (m, 3H), 1.58 (ddd, J = 11.4, 9.3, 5.7 Hz, 1H), 1.53 – 1.45 (m, 2H),
1.41 (d, J = 8.0 Hz, 18H), 1.38 – 1.27 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.29,
170.24, 170.19, 154.78, 153.95, 142.30, 142.03, 139.72, 139.67, 133.58, 127.06, 126.95,
126.81, 126.13, 126.12, 125.48, 123.57, 123.54, 118.40, 118.38, 80.27, 78.07, 65.77, 65.53,
52.05, 52.00, 45.54, 37.78, 31.12, 30.81, 27.32, 26.97, 26.73, 26.40, 20.95. MS (ESI)
calculated for C42H53N3O9, m/z 743.38, found 766.36 (M + Na)+.
Synthesis of compound 79: (S)-2-Amino-6-((R)-4-carboxy-4-
dodecanamidobutanamido) hexanoic acid: 1H NMR (500 MHz, MeOD) δ 4.35 (dd, J =
8.9, 4.9 Hz, 1H), 3.74 (t, J = 5.9 Hz, 1H), 3.24 – 3.12 (m, 2H), 2.30 – 2.13 (m, 5H), 1.95 –
1.80 (m, 3H), 1.66 – 1.37 (m, 7H), 1.31 – 1.27 (m, 15H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR
(126 MHz, MeOD) δ 176.28, 175.26, 174.74, 173.09, 54.56, 53.07, 39.70, 36.88, 33.15,
32.90, 31.17, 30.61, 30.59, 30.50, 30.35, 30.31, 30.23, 30.16, 29.73, 28.66, 26.78, 23.59,
23.11, 14.54. MS (ESI) calculated for C23H43N3O6, m/z 457.32, found 458.35 (M + H)+.
NF-κB induction
The induction of NF-κB was quantified using HEK-Blue™ cells as previously described by
us.10;51 HEK293 cells stably transfected with human Nod1 and alkaline phosphatase (sAP)
were obtained from InvivoGen (San Diego, CA), and were maintained in HEK-Blue™
Selection medium containing zeocin and normocin. Stable expression of secreted alkaline
phosphatase (sAP) under control of NF-κB/AP-1 promoters is inducible by Nod1 agonists,
and extracellular sAP in the supernatant is proportional to Nod1-mediated NF-κB induction.
HEK-Blue cells were incubated at a density of ~105 cells/mL in a volume of 80 μL/well, in
384-well, flat-bottomed, cell culture-treated microtiter plates until confluency was achieved,
and subsequently graded concentrations of compounds. sAP was assayed
spectrophotometrically using an alkaline phosphatase-specific chromogen (present in the
HEK-detection medium as supplied by the vendor) at 620 nm.
Experiments involving human blood
Human blood was obtained from healthy adults by antecubital venipuncture in accordance
with University of Kansas Human Subjects Experimentation protocols (Protocol # HSCL
12397).
Phosflow™ flow cytometric assay for p38MAPK
Assays were performed as described by us previously.10;38;52 Briefly, 1 mL aliquots of fresh
whole blood, anticoagulated with heparin were incubated with 25 μL an equal volume of
graded concentrations of compounds diluted in saline for 15 minutes at 37°C. Erythrocytes
were lysed and leukocytes were fixed in one step by mixing 200 μL of the samples in 4 mL
pre-warmed Whole Blood Lyse/Fix Buffer (Becton-Dickinson Biosciences, San Jose, CA).
After washing the cells at 500 g for 8 minutes in buffer, the cells were permeabilized in ice-
cold methanol for 30 min, washed twice in phosphate-buffered saline and transferred to a
Millipore MultiScreen BV 1.2μ filter plate and stained with either phycoerythrin (PE)-
conjugated mouse anti-p38MAPK (pT180/pY182; BD Biosciences) mAb, or a matched PE-
labeled mouse IgG1 κ isotype control mAb for 60 minutes. The cells were washed twice in
the plate by aspiration as per protocols supplied by the vendor. Cytometry was performed
using a BD FACSArray instrument in the single-color mode for PE acquisition on 20,000
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gated events. Post-acquisition analyses were performed using FlowJo v 7.0 software
(Treestar, Ashland, OR).
CD11b flow cytometric assay
Assays were performed as described by us previously.10;38;52 Briefly, 1 mL aliquots of fresh
anticoagulated whole blood were incubated with 25 μL of graded dilutions of the
compounds for 1 hour at 37°C. Negative (saline) controls were included in each experiment.
Samples were placed on ice for 15 minutes before 20 μL of anti-CD11b/Mac-1 antibody
(Becton-Dickinson) were added to each sample tube and allowed to incubate on ice for 30
minutes. This 0°C incubation step prevented internalization of antibody, and ensured
staining of only extracellularly expressed CD11b. Erythrocytes were lysed and leukocytes
were fixed in one step by mixing 200 μL of the samples in 4 mL pre-warmed Whole Blood
Lyse/Fix Buffer (Becton-Dickinson Biosciences, San Jose, CA). After washing the cells
twice at 200 g for 5 minutes in CBA buffer, the cells were transferred to a 96-well plate.
Flow cytometry was performed using a BD FACSArray instrument in the single-color mode
for PE acquisition on 20,000 gated events. Post-acquisition analyses were performed using
FlowJo v 7.0 software.
Transcriptomal profiling in whole human blood
Assays were performed as described by us previously.10 Briefly, peripheral blood
mononuclear cells (PBMCs) isolated from fresh, heparin-anticoagulated human blood was
stimulated with 20 μg/mL of the compounds for two hours, and total RNA was extracted
from treated and negative control PBMC samples with QIAamp RNA Blood Mini Kit
(Qiagen). 4 μg of each of the RNA samples was used for transcriptomal profiling,
employing the Human Genome GeneChip U133 plus 2.0 oligonucleotide array (Affymetrix,
Santa Clara, CA). Established standard protocols at the KU Genomics Facility were
performed on cRNA target preparation, array hybridization, washing, staining and image
scanning. The microarray data were collected using the Affymetrix GeneChip Command
Console Software (AGCC) and then subjected to quality assessment before further analyses.
QC criteria included low background, low noise, detection of positive controls, and a 5′/3′
ratio of < 3.0. To facilitate direct comparison of gene expression data between different
samples, the GeneChip data were first subjected to preprocessing, which included scaling of
data from all chips to a target intensity value of 500 (in Affymetrix Expression Console
Software), and further normalization in GeneSpring GX (Agilent Technologies, Santa Clara,
CA). Prior to identifying target genes, genes that were detected as non-expressed in all
samples, i.e., those with absence (A) cells were filtered out. Genes whose expression was
changed by our compounds by at least 2-fold (compared to the negative control) were
identified to be differentially expressed. Pathway analyses of gene expression were
performed using IPA® (Ingenuity Systems, Redwood, CA).
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Abbreviations
AP-1 Activator protein-1
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CD Cluster of differentiation
DAP Diaminopimelic acid
DMAP 4- Dimethylaminopyridine
EC50 Half-maximal effective concentration
ESI-TOF Electrospray ionizationtime of flight
FmocCl Fluorenylmethyloxycarbonyl chloride
Glu Glutamic Acid
HBTU O-Benzotriazole- N,N,N,N′-tetramethyl uronium hexafluorophosphate




Nod1 Nucleotide oligomerization domain-1
Nod2 Nucleotide oligomerization domain-2
NLR Nod like receptor
p38MAPK p38 Mitogen activated protein kinase
PBMCs Peripheral blood mononuclear cells
PE Phycoerythrin
PRRs Pattern recognition receptors
RIG-I Retinoic acid inducible gene-I
RNA Ribonucleic acid
sAP Secreted alkaline phosphatase
SAR Structure activity relationship
Th1 Helper T lymphocyte, type 1
Th2 Helper T lymphocyte, type 2
TLR Toll like receptor
TREM-1 Triggering Receptor Expressed on Myeloid Cells-1
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A. NF-κB induction activity in stable transfectants of HEK-293 cells expressing human
Nod1. B. Rank-order plot of potencies (EC50 values) of iE-DAP analogues.
Agnihotri et al. Page 31














Dose-responses of p38 MAP kinase (A) and CD11b (B) induction in the granulocytic
population in whole human blood by 16 and 27 determined by flow cytometry.
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Pathway analysis of transcriptomal activation patterns in human PBMCs exposed to 20 μg/
mL of 16 and 27. The dashed line corresponds to the threshold of −log (base 10) value for P
= 0.05 (after Benjamini-Hochberg multiple testing correction).
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Reagents: i. ROH, HBTU, TEA, DMAP, DMF; ii. (a) CF3COOH (b) FmocCl, Na2CO3,
Dioxane, H2O; iii. (a) (Boc)2O, TEA, H2O (b) R′OH, HBTU, DMAP, TEA, DMF; iv. (a)
HCl-dioxane (b) (Boc)2O (1eq.), TEA, MeOH; v. PS-Carbodiimide, PS-DMAP, CH2Cl2.
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Reagents: i. 30% Piperidine, CH2Cl2; ii. C11H23COCl, pyridine, DMAP; iii. (a) H2,
Pd(OH)2/C, MeOH, 60 psi (b) CF3COOH; iv. (a) CF3COOH (b) C11H23COCl, TEA,
CH2Cl2; v. H2, Pd(OH)2/C, AcOH, MeOH, 60 psi; vi. CF3COOH; vii. (a) C11H23COCl,
pyridine, CH2Cl2 (b) H2, Pd(OH)2/C, MeOH, 60 psi; viii. C11H23CHO (1eq.), MP-CNBH3,
CH2Cl2, MeOH, AcOH; ix. RCHO(excess), MP-CNBH3, CH2Cl2, MeOH, AcOH; x. 1H-
Pyrazole-1-carboxamidine.HCl, pyridine, MW irradiation, 60°C; xi. H2, Pd(OH)2/C, MeOH,
60 psi; xii. N,N′-Di-Boc-1HPyrazole- 1-carboxamidine•HCl, pyridine, THF, 50°C.
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Reagents: i. (a) 30% Piperidine, CH2Cl2 (b) (Boc)2O, TEA, MeOH; ii. (a) Chlorotris
(triphenylphosphine) rhodium(I), EtOH, H2O, reflux (b) C11H23OH, HBTU, DMAP, TEA,
DMF; iii. (a) H2, Pd(OH)2/C, MeOH, 60 psi (b) CF3COOH; iv. (a)
Chlorotris(triphenylphosphine) rhodium(I), EtOH, H2O, reflux (b) C11H23NH2, HBTU,
TEA, DMAP, CH2Cl2; v. (a) Chlorotris (triphenylphosphine) rhodium(I), EtOH, H2O,
reflux (b) ROH, HBTU, DMAP, DMF; vi. (a) 30% Piperidine, CH2Cl2 (b) C11H23COCl,
pyridine, DMAP; vii. (a) 30% Piperidine, CH2Cl2 (b) 1H-Pyrazole-1- carboxamidine•HCl,
pyridine, MW irradiation, 60°C.
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Reagents: i. 30% Piperidine, CH2Cl2; ii. (a) (Boc)2O, TEA, MeOH (b) H2, Pd(OH)2/C,
MeOH, 60 psi (c) C11H23SH, HBTU, DMAP, TEA, DMF; iii. CF3COOH; iv. C11H23COCl,
pyridine; v. (a) H2, Pd(OH)2/C, MeOH, 60 psi (b) CF3COOH.
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Reagents: i. Fmoc-GABA-OH, PS-Carbodiimide, PS-DMAP, CH2Cl2; ii. (a) 30%
Piperidine, CH2Cl2 (b) C11H23COCl, pyridine; iii. (a) H2, Pd(OH)2/C, MeOH, 60 psi (b)
CF3COOH; iv. Glutaric anhydride, CH2Cl2; v. C11H23OH, HBTU, DMAP, TEA, DMF.
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Reagents: i. BnOH, p-TSA, reflux; ii. (a) BnOH, HBTU, DMAP, DMF (b) 30% Piperidine,
CH2Cl2; iii. (a) PhCH2OCOCl, Na2CO3, Dioxane, H2O (b) CF3COOH; iv. (a) (Boc)2O,
TEA, MeOH (b) H2, Pd(OH)2/C, MeOH, 60 psi.
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Reagents: i. PS-Carbodiimide, PS-DMAP, TEA, CH2Cl2; ii. 30% Piperidine, CH2Cl2; iii.
C11H23COCl, pyridine; iv. H2, Pd(OH)2/C, MeOH, 60 psi; v. CF3COOH.
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Table 1
EC50 values of hNod1 agonistic activities of analogues
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Cmpd Structure EC50 (nM)
77 0.57
79 0.96
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Table 2
Interleukin Transcriptomal Responses in Human PBMCs exposed to 20 μg/mL of 27
Probe Set ID Fold change Regulation Gene Symbol Gene Title
220745_at 30.39 up IL19 interleukin 19
205207_at 29.54 up IL6 interleukin 6 (interferon, beta 2)
210118_s_at 14.34 up IL1A interleukin 1, alpha
220322_at 11.10 up IL1F9 interleukin 1 family, member 9
216876_s_at 10.56 up IL17A interleukin 17A
216244_at 8.27 up IL1RN interleukin 1 receptor antagonist
212659_s_at 8.19 up IL1RN interleukin 1 receptor antagonist
216243_s_at 7.54 up IL1RN interleukin 1 receptor antagonist
207901_at 6.13 up IL12B interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte
maturation factor 2, p40)
207906_at 5.99 up IL3 interleukin 3 (colony-stimulating factor, multiple)
212657_s_at 4.94 up IL1RN interleukin 1 receptor antagonist
39402_at 4.45 up IL1B interleukin 1, beta
205067_at 4.14 up IL1B interleukin 1, beta
224071_at 4.00 up IL20 interleukin 20
221165_s_at 3.87 up IL22 interleukin 22
207433_at 3.62 up IL10 interleukin 10
211269_s_at 3.62 up IL2RA interleukin 2 receptor, alpha
206341_at 3.57 up IL2RA interleukin 2 receptor, alpha
206569_at 3.41 up IL24 interleukin 24
227997_at 3.17 up IL17RD interleukin 17 receptor D
222223_s_at 3.15 up IL1F5 interleukin 1 family, member 5 (delta)
211506_s_at 2.29 up IL8 interleukin 8
224262_at 2.05 up IL1F10 interleukin 1 family, member 10 (theta)
206295_at 2.03 up IL18 interleukin 18 (interferon-gammainducing factor)
1555431_a_at 4.05 down IL31RA interleukin 31 receptor A
220056_at 3.69 down IL22RA1 interleukin 22 receptor, alpha 1
207008_at 2.75 down IL8RB interleukin 8 receptor, beta
220663_at 2.06 down IL1RAPL1 interleukin 1 receptor accessory proteinlike 1
205227_at 2.02 down IL1RAP interleukin 1 receptor accessory protein
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